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Abstract
Luminescent sub-100 nm particulates continuously generate immense research
interest in the biomedical field for imaging, theranostics, and optogenetics. Conventionally, upconversion nanoparticles or UV activated semiconductors are studied,
however these materials are limited by biological barriers such as the skin which reduces the penetration depth of these excitation sources, tissue’s auto-fluorescence,
and toxicity. One approach to overcome these challenges is to use nanoscintillators
(sub-100 nm materials that can generate visible light using high energy excitation
sources such as x-rays) which can generate light locally to the human body.
Numerous scintillators have been reported since the discovery of x-rays from
the famous Roentgen experiment. The brightest and most commonly used scintillator
in the biomedical field is a single crystal lutetium oxyorthosilicate doped with cerium
(Lu2 SiO5 :Ce, LSO:Ce) for its high optical output, short decay time, and minimal
self-absorbency. Alternative nanoscintillators that have potential for biomedical applications are different derivatives of the silicate family such as lutetium pyrosilicate
and yttrium pyrosilicate. These crystal can be synthesized using different high temperature melt-growth processes. Consequently, the affinity for nanoparticles to sinter
makes this a difficult material’s challenge.
This dissertation is presented in three parts on a technique that can synthesize non-aggregated and highly crystalline sub-100 nm refractory particulates that
ii

can scintillate. First the synthetic technique coined the high temperature multicomposite reactor is presented where monodisperse yttrium and lutetium pyrosilicate (Lu2 Si2 O7 :Ce) nanoparticles were synthesized above 1000◦ C. Afterwards different
energy transfer mechanisms were examined by using different lanthanide activators
(Ce3+ , Tb3+ , and Eu3+ ) to target specific wavelength emissions and increase the overall optical output. Lastly, these nanoscintillators were surface modified with different
organic moieties (organic dyes, bovine serum albumin, and polypropargyl acrylate)
that can couple to different biological conjugates using a copper-catalyzed azidealkyne cycloaddition reaction. The work presented here will emphasize the biomedical applications where the scintillators synthesized have the potential to couple to
light sensitive protein known as opsins for optogenetics. The organic compounds that
will be investigated are bovine serum albumin to increase the nanoparticles biocompatibility, indocyanine green dye as an infrared biotracer, and rose bengal for x-ray
induce photodynamic therapy.
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Chapter 1
Introduction
Nanoparticles have been long researched in the biomedical field for potential
applications in theranostics, MRI contrast agents, drug delivery, and modulation of
neurological functions (optogenetics) [1–4]. Common inorganic nanoparticles applied
in the biomedical field are metals (i.e. Au), oxides (i.e. Fe2 O3 ), and fluorides (i.e.
NaYF4 ) which are synthesized by a controlled bottom-up approach [5–7]. This work
serves to expand the current technology available in nanotechnology by 1) creating a
process to reduce sintering of refractory nanoparticles that can scintillate, 2) having
the nanoscintillators generate specific wavelengths of light that can stimulate light
sensitive proteins (opsins) and 3) coupling the inorganic nanoparticle with organic
moieties to create multiple functionalities for biomedical applications.
More specifically, chapter two discusses a novel technique coined the high temperature multi-composite reactor (HTMcR). This technique is a multi-step process
that encases a inorganic core-shell particulate with a cross-linked polymer. By carbonizing the organic component, the inorganic particulate can recrystallize with one
another while the amorphous carbon prevents particle-particle contact. Two refractory scintillators were synthesized using this method yttrium pyrosilicate (Y2 Si2 O7 )
1

and lutetium pyrosilicate (Lu2 Si2 O7 ). A poly(divinylbenzene) sacrificial delamination layer was used during the carbonation process and both the nanoscintillators
were doped with cerium. The work presented in chapter two focuses on the development and validation of the HTMcR by extensive annealing experiments. Electron
microscopy was used to confirm the aggregation state, particle size distribution, and
elemental mapping of these nanoparticles. While X-ray diffraction was used to determine the crystal structure and crystallite size. Cerium was doped into both particulates as a model system to determine the structure-property relationship of the
different annealed crystals by photoluminescence and radioluminescence.
Chapter three incorporates different lanthanide species in the pyrosilicate crystal lattice to generate emission wavelengths across the visible spectrum that can couple to different light sensitive proteins (opsins). This work focuses on cerium, terbium,
and europium where different series of mono-, co-, and tri- dopants were studied to
generate the brightest scintillator in the yttrium pyrosilicate crystal lattice. In the
mono-doped series, different concentrations of the respective dopants were incorporated in the host lattice. Optical measurements from X-ray and Uv irradiation were
performed to ensure energy transfer between the dopants and potential biological
conjugates. The co-doped series focuses on cerium and terbium to enhance terbium’s
emission. In this series cerium acts as a sensitizer and terbium as the activator. The
last series will focus on terbium as an intermediate for energy transfer between cerium
and europium to reduce metal-metal charge transfer. Each of the multi-doped series
were compared to the mono-doped series where each energy transfer process increased
the optical output of the scintillator. Electron microscopy was also used to determine
the aggregation state and elemental distribution of these highly doped particulates.
X-ray diffraction was used to confirm no polymorphs were formed when embedded
with different dopants.
2

Chapter four focuses on adding new functionalities to the nanoscintillators
through surface modification with organic moieties by copper-catalyzed azide-alkyne
cycloaddition (CuAAC) click chemistry. This chemistry utilizes a copper(I) catalyst
where a compound with an azide group and another compound with an alkyne group
forms a covalent bond. Two methods were used to modify the surface of the nano
yttrium pyrosilicate. The first method used (3-Azidopropyl)trimethoxysilane (azsil)
directly bonded to the particulates surface, followed by CuAAC with different alkyne
functionalized molecules. The second method to surface modify the nanoparticles
was to polymerizes propagyl acrylate on the surface of yttrium pyrosilicate. This
surface modification is an alternative CuAAC approach for compounds with a azide
functional group. Both methods can create a particulate composite with an scintillating inorganic core and a polymeric shell that can generate different functionality
and are only constrained to the limitation of CuAAC. In this chapter azide modified
particulates bonded to alkyne modified molecules were primarily explored. Three
alkyne functionalized organic moieties were explored for their unique properties. The
first organic moiety bonded to the nanoscintillator was alkyne functionalized BSA
(alkBSA) which can reduce cytotoxicity and delivery nanoparticles inside the cells.
The second molecule explored was alkyne functionalized indocyanine green dye (alkICG) a FDA approved dye that can be used as a infrared tracer inside the body. The
last compound explored is alkyne functionalized rose bengal (alkRB), a photosensitizer that can excite a triplet state oxygen to its singlet state and generate reactive
oxygen species (ROS). Each organic molecule described above, when coupled with
X-ray luminescent emitter, have unique applications in the biomedical field that have
ample opportunities to be explored.
Lastly, chapter five summarizes the work presented and presents an outlook
on the potential of the HTMcR. The work has been structured around the HTMcR
3

for nanoscintillators from development, the X-ray luminescence properties with different rare earth dopants, and particulate functionalization for biomedical applications
via CuAAC. This work primarily focuses on a silica core and a yttrium pyrosilicate
shell, however the HTMcR can expand to other crystals that previously cannot be
synthesized at the nanoscale due to thermal constraints.

1.1

Advances in X-ray nanotechnology for biomedical applications
In 1895 Wilhelm Roentgen stumbled upon a new electromagnetic radiation

known as X-rays which were first used to distinguish density of different matter [8].
In one year the new ray was used to image kidney stones and by the early 1900’s
X-rays were ubiquitous in radiotherapy. With the advancement of computers and
coupling the deep penetration of X-rays new diagnosis imaging tools were created
for medical professions such as computed tomography to obtain detailed images of
organs, tissues, and bones [9]. As higher energy radiation became more prominent
in medical imaging the discovery for better scintillators (materials that can generate
visible photons when excited by a high energy radiation source) was required for
the detectors as seen in positron emission tomography which can measure changes
in metabolic and physiological processes [10]. In the past 20 years researchers have
coupled nanotechnology and contrast agents in the form of a scintillator with X-rays
to develop new therapeutics and theranostics techniques such as X-ray optogenetics
and X-ray induced photodynamic therapy [11, 12]. The use of X-rays have become
more prominent in medical diagnostics due to its deep tissue penetration that visible
and near infrared light cannot penetrate.
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X-rays can be used to observe the interaction of nanoparticle based drugs
in biological environments that visible and near infrared imaging techniques cannot
achieve due to scattering’s wavelength dependence (λ−4 ). The use of fluorophore
analyte can provide exceptional spatial resolution down to a few nanometers when
combined with super resolution and near field approaches [13, 14]. However, the optical excitation of fluorophores is limited due to the inhomogeneous state of biological
environment (i.e. blood and tissues) obscuring the incoming excitation beam, resulting in a reduction of the spatial resolution and the probability for beam reaching the
target [15]. Shifting the excitation energy into the ”biological window” of near infrared can partially alleviate the incoming energy from being absorbed and scattered,
however high resolution recordings in-situ is not possible between a nanoparticle drug
and cells using this methodology [16]. X-rays on the other hand carries enough energy to excite the inner shell electrons located in the orbital. This ability can enable
X-ray fluorescence imaging and X-ray absorption spectroscopy to directly inspect the
elemental species of the nanoparticle and precisely locate the nanoparticle drug in the
biological matrix in-situ [17, 18]. X-ray florescence imaging can be used to observe the
continuous uptake and distribution of cells and drugs with commonly used elements
such as gadolinium, gold, or iron [19]. In combination with computer tomography and
the ability for X-rays to differentiate between different electron density, phase contrast images can inspect the interaction between inorganic nanoparticles and tissues
in three dimensions [20]. The potential for the use X-rays to study nanoparticle based
drugs with biological tissues/cells opens new opportunities that visible and infrared
radiation cannot achieve due to scattering and its interaction with body.
The dangers of X-rays must be discussed if there is any potential to use this
form of radiation for therapeutics, diagnosis, or in-vivo analysis. Ideally the radiation source should leave the biological environment and the nanoparticle unaffected,
5

however severe exposure to X-rays can cause beam damage to biological molecules
and tissues. The risk of X-rays and its relationship to cancer is a complex matter;
for instance it has been reported that leukemia can occur when exposed to radiation of several hundred mSv however medical diagnosis X-ray’s in radiotherapy (∼10
mSV) increases the risk of cancer between 0.6 - 1.8% over 75 years [21, 22]. Many
factors contribute to radiation damage including exposure time, biological site/area,
radiation dosage, oxygen status, and tissue renewal rate; among these factors it has
been reported that acute high dose radiation may cause more biological damage than
chronic low dose exposure with the same total radiation dose due to tissue reconstruction [23]. Radioenhancers in the form of scintillators and transducers have been
applied in therapeutics to increase on-site radiation exposure to tumor cells or the
region of interest to reduce the overall radiation exposure [24]. Other synthetic protection against radiation damage are radioprotective agents such as amifostine and
palifermin to scavenge ROS generated by X-rays [25]. While the trade-off for the
deep penetration of X-rays is tissue and DNA damage, natural and synthetic method
have been developed to alleviate the negative side affects of X-rays with ongoing research to reduce DNA damage such that X-rays become more prominent in biomedical
theranostics.

1.2

Synthesis of nanoparticles and their different
morphology
Nanomaterials are often classified as materials with atleast one dimension be-

tween 1 to 100 nm, often with unique properties not observed in its bulk state. While
civilizations have used nanomaterials early as 4500 years ago in ancient Egypt, the
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first scientific report on nanoparticles was in 1857 by Michael Faraday on colloidal
gold nanoparticles [26]. Faraday reported dissimilar optical characteristics of these
colloids compared to their bulk state which, was later explained by Gustav Mie in
1908 [27, 28]. By 1940 silica nanoparticles were first synthesized as an alternative for
carbon black [29]. Currently, silica is a primary candidate for biomedical applications
and is generally regarded as non-toxic towards cells. One example on silica’s toxicity towards human umbilical vein cell line is presented in Figure 1.1 [30]. In this
example the report of sub-100 nm silica can be seen as toxic, however the reporters
should have normalized by particles per cell since nanomaterials have a higher surface
to volume ratio. This would result in a greater amount of nanoparticles for smaller
size particulates under the same concentration. In regards to toxicity, the smaller
nanoparticles studied by concentration rather than particle per cell would cover more
surface area of the cell and hinder cellular activities, which ultimately leads to cell
death. In the 21st century, a plethora of different nanomaterials are being researched
in the scientific community that span from oxides, fluorides, quantum dots, metals,
organic dyes, and polymers [31]. These nanomaterials are currently being studied
for their unique properties to couple to biological conjugates as drug carriers, image
contrast agents, and therapeutics [32]. Currently, manufactured nanomaterials are
incorporated in commercial bulk materials to improve their current strength, conductivity, lightness, and/or durability [33].
Two methods are used to synthesize sub-100 nm colloids: a bottom-up approach and a top-down approach [34]. The former builds nanomaterials from an
atomic scale to a nanoscale where the personnel has greater control in the materials
composition, structure, and purity [35]. The top-down is the reverse process where
a bulk materials is milled or chemically etched down to the nanoscale [36]. Research
in nanomaterials primarily focus on the bottom up approach where variations in
7

Figure 1.1: Toxicity of silica nanoparticle towards human umbilical vein cell line. In this study, the
reporters presents a size and concentration dependency on cell viability with smaller silica nanoaprticles being more toxic [30]. However it should be noted that decreasing the size of the nanoparticles
would increase the surface to volume ratio resulting in a higher population of nanoparticles and may
hinder cellular activities. Copyright 2009. Reproduced with permission from John Wiley and Sons.
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emulsion polymerization and hot injection methods are employed. From a classical
nucleation perspective and for a spherical geometry, the bottom-up approach is a
homogeneous nucleation process which has a free energy (∆G) that can be expressed
as [37]:
4
∆G = − πr3 |∆Gv | + 4πr2 γ
3

(1.1)

Where r is the radius of the particle, ∆ Gv is the bulk free energy per unit
volume, γ is the surface energy per unit area. The critical radius (rc ) of the particle
can be determined by taking the first derivative and minimizing the free energy to
zero which is expressed as:
2γ
∆Gv

rc =

(1.2)

The activation energy of the critical free energy (∆Gc ) is determined when the
critical radius is substituted back into the free energy term:

∆Gc =

16πγ 3
∆G2v

(1.3)

The critical free energy describes activation energy and thus rate of nucleation
(J(T,∆Gc )) is a statistical process that can be expressed as an Arrhenius equation:

J(T, ∆Gc ) = Aexp(

−∆Gc
)
kB T

(1.4)

where A is a constant, T is the absolute temperature, and kB is the Boltzmann constant. A three stage process from the LaMer’s model is commonly used to
depicted homogeneous nucleation (Figure 1.2). In the first stage the concentration
of monomers are increased until a critical concentration (Cs ) is reached and homo9

geneous nucleation is possible. Afterwards when the concentration increases past its
activation energy rapid burst nucleation occurs. Lastly, the saturation level falls below the self-nucleation level of the monomer’s concentration ending the nucleation
process and particle growth begins. In wet chemistry, homogeneous nucleation is applied in the hot injection or heat-up method to synthesize metallic (i.e. Au, Ag, Pt),
oxides (i.e. Fe2 O3 ), fluoride(NaF, NaGdF4 ), or quantum dot (CdSe) nanoparticles.
The precise control in the nucleation and growth reaction of different nanoparticle
can be tailored to control the average particle size and distribution.
More advanced techniques were latter applied using heterogeneous nucleation
where a particle’s surface reduces the energy barrier of a overgrowth phase for nucleation and growth. The free energy barrier model is similar to that of homogeneous
nucleation with the inclusion of a contact angle function (f(θ)) [39]. On a flat surface

∆Ghetero = ∆Ghomo f (θ)

(1.5)

and on a curved surface

f (θ) =

(1 − cosθ)2 (2 + cosθ)
4

(1.6)

Heterogeneous nucleation allowed researchers to create unique heterostructure nanoparticles that can be categorized into three classes: 1) porous structure, 2)
polymer-nanoparticle composites and 3) hybrid nanoparticles (Figure 1.3). Hollow
and porous nanoparticles are commonly applied to drug delivery owing to their high
surface area and vacant structure. Among the different porous nanoparticles, mesoporous silica is has been a staple in this research due to their excellent biocompatibility
and well established synthetic process [40]. This class of nanoparticles can be synthesized using controlled oxidation methods and/or chemically etching of a composite
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nanoparticle to create yolk-shell or hollow nanoparticles [41]. Polymer nanoparticle composites applies a polymer coating on a inorganic nanoparticle. This class of
nanoparticle is one of the most versatile and straightforward method to produce multifunctional nanoparticle due to the abundance of different organic moieties and their
functionalities [42]. While organic capping agents are used to prevent agglomeration
during the synthesis of nanoparticles other ligands can be substituted onto the surface
of the inorganic particulates and add new functions [43]. These functional expansion
can range from binding drugs (i.e. Doxorubicin), imaging probes (i.e. rhodamine b),
and targeting agents (i.e. folic acid) [44]. These organic agents can be covalently
bonded onto the surface of different inorganic nanoparticles through ligand exchange,
encapsulations, ionic stabilization, or click chemistry [45]. The last heterostructure
class is hybrid nanoparticles where the particulate is composed of two or more inorganic materials. The benefits of using this architecture is to combine two distinctive
properties from different inorganic materials into a singular nanoparticle [46]. The
most popular biomedical design for this class is a core with either a optical or magnetic property and a bioinert shell as a passivation layer that can reduce the dangling
bonds on the surface of the core and/or generate a generate a secondary function
[47]. Nowadays multiple materials compiled into a single nanoparticle are ubiquitous
in biomedical research. All three types of structures described are more advantageous for biomedical applications compared to their singular material counterpart
with improved properties such as multifunctionality, increased stability, reduced toxicity and, better conjugation to biomolecules. Through a series of homogeneous and
heterogeneous nucleation process new nanoparticles are being discovered to advance
biomedical research.
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Figure 1.2: (a) Energy diagram of between the competing forces of a particulates surface and
bulk state. (b) Lamer’s model of homogeneous nucleation [38]. Reproduced with permission from
J. Polte. CrystEngComm published by Royal Society of Chemistry, 2015.

Figure 1.3: Different structures of nanoparticles [48]. Copyright 2018. Reproduced with permission
from John Wiley and Sons.
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Figure 1.4: (a) Timeline of different scintillators discovered between 1900-2000 [52]. Copyright
2002. Reproduced with permission from Elsevier. (b) Photon yields of different scintillators [53].
Copyright 2001. Reproduced with permission from Elsevier.

1.3

Scintillators
Scintillators are a class of materials that can absorb and convert high energy

radiation or charged particles (X-rays, γ-rays, neutrons) into visible photons. In
1948 NaI:Tl was discovered to have scintillating properties and have been applied
to many modern high energy detectors for nuclear security physics research (Figure
1.4) [49]. Scintillators have also been expanded into many biomedical devices such as
positron emission tomography, computer tomography, and radiography [50]. As the
applications of scintillators grow, new prospective scintillators are being developed as
seen in Figure 1.4a [51].
While many ionization energies exist, X-rays are commonly used because it is
easier to generate, is a deep penetration excitation source, and is non-destructive. The
scintillation mechanism is a complex process that is typically simplified into a three
step process (Figure 1.5) [54]. The first step is called the conversion stage where
the ionized energy is absorbed by the scintillator to generate electron-hole pairs in
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the conduction and valence band which will generate secondary pairs by the cascade
effect [55]. During this stage if the electron energy is less than the ionization threshold
the electrons and holes will thermalize to the bottom of the conduction band and top
of the valence band respectively. The second stage is called energy carrier migration
where the electrons and holes transfer its kinetic energy through the crystal lattice
and attempts to reach the luminescent center. During this stage the charged carriers
can be trapped through crystal lattice defects, which can overall quench or delay the
scintillation process. The final step is the relaxation/emission stage where the energy
carriers recombine at the luminescent center and release a photon. The quantum
efficiency for the scintillation process has been reported by the following [10]:

η = βSQ

(1.7)

where η is the number of visible photons created when excited by ionized
radiation, β is the number of electron-hole pairs created when a scintillator absorbs the
ionized radiation, S is the charged carrier’s transfer efficiency to reach the luminescent
center, and Q is the radiative efficiency of the luminescent center.
The ideal scintillator is influenced by the users requirements and certain parameters must be optimized for the materials end use [56]. Universally a ideal scintillator will have a high density with a high atomic number (Z) which increases the
stopping power of the scintillator, photo-fraction (∼Z4 ), and shower containment [57].
In general, a materials ability to attenuate X-rays can expressed by the following:

µ = ρZ 4 /AE 3

(1.8)

where µ is the X-ray attenuation coefficient, ρ is the density of the material,
A is the atomic mass, and E is the X-ray photon energy.
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Figure 1.5: Simplified scintillation mechanism.

Consequently, this reduces the volume and material needed to produce a scintillating device. Light yield (photons generated per incident energy) is also an important factor for devices that require high degree of accuracy, energy resolution,
and spatial resolution such as positron emission tomography. In connection with
light yield, the emission wavelength must be considered when choosing a photodetector. Fast signal rises and short decay time of the scintillator are important for high
event rate applications such as high energy physics detectors and medical imaging
techniques that require the absence of afterglow. The material’s durability under
radiation and its environment must also be consider, for example the crystal should
be non-hygroscopic and if no suitable substitute is available the crystal should be
encased in an airtight container (i.e. NaI). Lastly if the end use of these scintillators
are to be applied inside the body the particulates used have to non-toxic. In practice
it is generally impossible to synthesize a scintillator that combines all the properties
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stated above. A trade off between the different properties is always present where the
user’s requirements will prioritize certain properties over another. For example the
in X-ray induced photodynamic therapy toxicity will always be the most important
factor, following light yield, and emission wavelength [58]. While for computer tomography, material stability, light output under different temperature, and minimum
afterglow are critical to obtain the thousands of projection per second for one subject
slice [59].
Scintillators are commonly inorganic materials with low structure defects, low
non-desired impurities, and uniform distribution of dopants throughout the crystal. The leading growth method to synthesize commercial scintillating crystal is the
Czochralski method. This method is a melt-growth technique where the starting
materials is melted in a crucible and a crystal seed is inserted, pulled upwards at
steady state with continuous rotation, and then held at a temperature slightly above
the freezing point [60]. This process continues until a ingot is formed which can be
shaped and polished to a desired shape and size. A high degree of crystal engineering
is involved in this process and presented in Table 1 [61]. Many different semiconductor, oxides, silicates, and halides have been synthesized using this technique, however
this process is suited for scintillators that are at the millimeter scale or above [62].
For biomedical theranostics or devices that require a size scale in the nanometer range
homogeneous nucleation and growth, discussed above, is the ideal synthetic method
[63].
Table 1.1: Parameters for Czochralski method
Parameters
crucible
atmosphere
melt
seed
pulling
thermal

Factors to control
size, shape, melting point, material’s composition, and corrosion
pressure, and flow rate
composition of starting materials meniscus
size, composition, orientation, and structure
pulling rate and rotation rate
thermal gradients
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Influence on final crystal
impurities
quality of crystal
crystal phase and crystal structure
quality of crystal
diameter of ingot
aspect ratio of ingot and crystal phase

1.4

Rare earth luminescence in inorganic phosphors
The rare earth lanthanide series are composed of 15 elements from La (57)

- Lu (71), with electron configuration of [Xe]6s2 fn (n = 0 - 14) [64]. Current practice includes yttrium (Y) and scandium (Sc) as part of the lanthanoid family due
their similar chemical properties and their abundance in the minerals the rare earth
elements are found in [65]. The lanthanide series are unique due to their electron
configuration and primary exist in the same oxidation state (Ln3+ ). The electronic
transition of the lanthanide series is associated with the seven f orbitals where a
maximum of two electrons can exist with opposite spins (±) from Pauli’s exclusion
principle [66]. The possible micro state, where an electron can exist in a orbital can
be computed by the following:
14!
n!(14 − n)

(1.9)

where n is the number of electrons in the f orbital of the respective lanthanide.
A collection of the same micro states are expressed in spectroscopic terms of

(2S+1)

L,

where S is sum of the same spin term and L is the sum orbital value [67]. The sum
orbital value (0, 1, 2, 3, 4, 5, 6...) is express as capital letters (S, P, D, F, G, H, I...).
The ground state of a multielectron atom can be determined by Hund’s first and
second law which states that the largest spin multiplicity (2S+1) is the lowest energy
(Hund’s first rule) in addition, the largest sum orbital value has the lowest energy
(Hund’s second rule) [68]. The interaction between electrons and orbitals are not
independent and increases with atomic number. For the lanthanide series, spin-orbit
coupling dominates and the micro states are further split into

(2S+1)

LJ , where J is a

new quantum number to express spin-orbit coupling and is calculated by [69]:
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|J = S + L, S + L − 1, ...L − S|

(1.10)

Hund’s third rule states that the new ground state would be the lowest J
number for elements with less than seven electrons in the f orbital and the highest J
number for elements with more than seven electrons in the f orbital.
The excited states from the lanthanide series are the other micro states determined above. The possible microstates for the lanthanide series are expressed in
the Dieke’s partial energy diagram for the low symmetry crystal ReF3 (Figure 1.6)
[70]. Figure 1.6a provides the traditional free energy diagram of the lanthanide
series however Gd3+ is incompletely identify and should be 8 S7/2 [71]. Furthermore,
the traditional Dieke diagram can be extended past 40,000 cm−1 as seen in Figure
1.6b which, provides new intraconfigurational 4fn transition from vacuum ultraviolet
radiation(λ < 200 nm) [72]. Three possible interactions can originate when these
rare earth elements are bonded to a ligand [73]. The first possible interaction is
charge transfer from the metal to ligand or ligand to metal transition which is often
characterized with absorbency and emission in the UV region. The second electron
transition is from the 4f-5d orbital where the optical emission and absorption is dependent on the crystal’s environment and is often seen as a broad spectral emission
(i.e. Lu2 SiO5 :Ce). The last possible transition is a intra-transition in the f orbital, a
Laporte forbidden transition in most cases however, is partially allowed due to strong
spin-orbit coupling in the lanthanide series. This transition is often characterized
with sharp emission spectra and long life time.
Commonly, rare earth inorganic luminescent materials are composed of a activator in the form of lanthanide element(s) and a matrix, in certain cases additional
impurities are purposefully introduced to enhance luminescence [74]. When these
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a)

b)

Figure 1.6: (a) Dieke’s energy diagram of the different rare earth lanthanides in a ReF3 lattice
[70]. Copyright 1963. Reproduced with permission from G. H. Dieke and H. M. Crosswhite. Appl.
Opt. published from OSA Publishing. It should be noted that Gd3+ is incomplete. (b) Extended
Dieke diagram in the vacuum ultra violet region [72]. Copyright 2000. Reproduced with permission
from Elsevier. It should be noted that only the strongest experimentally observed lines were included
for Sm3+ - Dy3+ and assignments of these ion states have yet to be calculated.
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rare earth impurities are doped in certain crystals they create defect levels for luminescence. Three types of conversion are possible: down shifting where a photon of
high energy is generates a lower energy photon, upconversion a process that takes two
or more lower energy photons to generate a higher energy photon, and downconversion where a higher energy photon is used to generate multiple lower energy photon
[75]. The first two cases are readily reported however no reported cases have been
found for downconversion and are only postulated. The combination of different rare
earth phosphors with different conversion process have stimulated the solid state and
biomedical industry as potential color tunable LED’s and theranostics, respectively
[76]. The optical properties of these rare earth materials are of great interest in the
biomedical field because they are unaffected by its host material, have narrow absorption and emission peaks, and large stoke shifts that can eliminate background noise
[77].

1.5

X-ray induced photodynamic therapy
Cancer has been a global health issue that medical professionals have been

working to find a permanent treatment. With different technology developed ranging
from chemotherapy, surgery, radiation treatment, immunotherapy, and nanotechnology (i.e gene therapy) the metastasis of cancer cells still plagues effective treatment
options [78]. In 1903 Niels Ryberg Finsen was awarded the Nobel prize in Physiology/Medicine for his discovery to treat lupus vulgaris with controlled light rays; his
work pioneered numerous biomedical studies using chemical and light [79]. In 1900
Oskar Raab discovered that the presence of different dyes when coupled with specific
light can inhibit cell movement and division [80]. This phenomenon was latter coin
photodynamic therapy (PDT), a technique that is currently being examined as an
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alternative treatment for malignant cell growth (Figure 1.7).
Broadly, three components are required to induce photodynamic therapy a
photosensitizer, a light source, and oxygen [82]. The photosensitizer molecule is required to absorb a specific wavelength of light that can be excited from its ground
state (singlet) to its excited state (triplet) and be localize to specific cells or tissues.
The second component is the administration of specific wavelength of light to activate the photosensitizer. The last requirement is that both the photosensitizer and
the administration of light are in a oxygen environment to produce two types of reactions. The first type of reaction (type I) is when the excited triplet state of the
photosensitizer transfers its electron to the cell membrane to form radicals, which
then can interact with oxygen to form ROS [83]. The second reaction (type II) is
that the excited photosensitizer interacts directly with oxygen to form ROS in the
form of a singlet oxygen. In both cases, PDT is based on energy transfer from the
photosensitizer to oxygen species found in tissues to generate ROS which ultimately
leads to cell death. The first in-vivo attempt of PDT was administered to rats in
1972 where the researchers reported tumor suppression for 10-20 days, however the
deeper regions of the tumor began to metastasis [84]. Three year later another group
of researchers reported the use of red-light at 600 nm activated PDT on mice with
mammary cancer [85]. No signs of tumor growth were observed in the mice when
PDT was administered using a deeper penetrating light source. In the past four
decades, numerous human trials were performed using PDT which showed promising
results for early stages of cancer and was only recommended for early stage patient
who cannot be operated [86]. Currently the more deadly and difficult to reach cancer
such as breast, head, neck, and pancreatic cancer patient had limited success due
specificity and potency of the photosensitizer.
A major field that is growing in the PDT community is the development of
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Figure 1.7: Principle of photodynamic therapy where a X-rays are absorbed by a scintillator
to generate visible photons that can be absorbed by a photosensitizer which can react with oxygen
species in the body to create reactive oxygen species and kill cancer cells [81]. Copyright 2020.
Reproduced with permission from W. Sun et al. Theranostics published by Ivyspring International
Publisher.
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photosensitizers that can couple with deeply penetrating light sources (i.e. IR and Xrays) [87, 88]. This was previously mentioned with the breakthrough of red light and
nowadays conventional PDT methods utilizes IR radiation coupled with NIR emitting
nanoparticles such as NaGdF doped with Er3+ , Yb3+ , and Tb3+ [12]. Low energy
wavelengths were sought after due to the strong absorption of endogenous molecules
(e.g. hemoglobin) below 700 nm [89]. Deep penetrating wavelengths should be between 700 nm - 1300 nm, however this low energy has been reported to be insufficient
to excite photosensitizers and generate ROS. Even in this optical window the penetration depth ranges from 1 - 12 mm in porcine conditions. Since 2006 a growing
interest in X-ray induced photodynamic therapy (X-PDT) has emerged [90]. In this
field a sub-100 nm scintillator coupled with a photosensitizer acts as a transducer for
incoming X-ray. X-PDT offers two solutions that were a challenge for IR induced
PDT 1) the deep penetration depth and high energy of X-rays can excite nanoscintillators that can create a cascade effect to generate ROS from a photosensitizer and 2)
X-rays allow whole-body metastasis control capable of generating both types of ROS
[91]. Of the many nanoparticles used in the biomedical field, rare earth elements have
the most influence in the X-PDT community. The rare earth elements used in solid
state technology are excitable by X-rays and/or attenuate X-rays to increase absorption efficiency [92]. Furthermore the majority of rare earth elements are f-f transitions
which, are Laporte forbidden therefore have long lifetime and can create persistent
luminescence [93]. This long afterglow has been proposed as a possible solution to
reduce X-ray exposure while the scintillator and photosensitizer are interacting with
one another to generate ROS. As research in theranostics grow so will the interest
in X-PDT and the use of X-ray luminescent nanoparticles, a field that is relatively
unexplored and has ample opportunities in theranostics.
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1.6

Optogenetics
In 1979, Francis Crick postulated that a prerequisite to study general theory

of the mind would require a technique that can manipulate a singular type of neuron
while leaving the other types of neurons unaltered [94]. Early optical efforts to control
cellular behavior involved lasers to inhibit cell behaviors by destroying them or control
cells with florescent labeled and genetically tagged cells. In 2005 a research group coin
the term optogenetics, a technique that combined both optical and genetic techniques
to control specific cells of living tissues with millisecond precision by using blue light
and genetically modifying mammalian neurons with Channelrhodopsin-2 (a blue light
sensitive ion channel that controls sodium ions from entering neurons) [95].
Optogenetics is a multistep technique that requires genetic alteration of a
specimen’s living tissue and uses light of specific wavelength to modulate the electric
potential of a specific cell (Figure 1.8) [96]. The first step of optogenetics is building
a genetic construct that can modify genes with opsins. This genetic construct is
then embedded in a virus that can selectively target certain neurons. Once the virus
is injected and the specimen expresses the genetic alteration, a surgical procedure
follows to insert a fiber-optic cable. This fiber-optic cable is used as a waveguide
to directly introduce light of a specific wavelength to the neurons and controls ion
channels from opening or closing. Optogenetics in-vitro experiments uses electrodes
sensitive to certain ions and studies the action potential of these of neurons, while
in-vivo studies monitors these action potentials with behavior studies [97].
Over the past decade and a half numerous opsins have expanded the optogenetics toolkit allowing greater flexibility for neuroscientists to use different wavelength of
light and time scales to control neurons [98]. Recently efforts in optogenetics are looking to replace fiber-optic cables with a less invasive medium to deliver light. Promising
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Figure 1.8:

(a) Conventional approach to optogenetics where a optical fiber cable is inserted
through a rodents cranial for neuromodulation. (b) Proposed non-invasive approach using X-rays
coupled with a scintillator to generate light for neuromodulation.
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results were reported on upconverting NaYF4 :Yb/Tm nanoparticles for optogenetics
due to the transparent window of endothelial cells in the IR region and the plethora
of knowledge to synthesize and control optical emissions of fluoride nanoparticles [99].
Nevertheless, the use of upconversion nanoparticles has its limitations similar to that
of its use in PDT. While infrared radiation is transparent to the mammalians skin
cells, its interaction with cranial matter reduces its intensity by ∼90% and can only
penetrate 2.5 mm of the human cortex (human cortex thickness varies between 2.5
mm - 5 mm) [100]. X-ray excitable nanophosphors have been proposed as an alternative particulate system due to X-rays deep tissue penetration and can be precisely
focused to certain region of the brain [101]. Proof of conception using scintillation
to induce neuromodulation was first performed in 2018 where a single crystal was
implanted into a rodent, however this method is still an invasive process and opens
up the possibility for a more non-invasive approach [102]. One approach that will be
discussed is the use of nanoscintillators with size between 100 nm - 200 nm which
can be injected intravenously, cross the blood brain barrier, and target specific opsins
that can undergo Förster resonance energy transfer (FRET) to control neurons.

1.7

Conclusion
While many have considered the synthesis of nanomaterials a mature field,

the high temperature requirement to crystallize rare earth silicate scintillators at the
nanoscale is a difficult materials problem that has never been solved due to the sintering. Historically, issues with high temperature crystallization of nanomaterials stem
from particle-particle contact between two or more particulates which will initiate
the first stages of sintering. It was hypothesized that if a physical barrier was present
during the annealing process of a core-shell nanoparticle, then the particulate would
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be isolated from one another and be unable to sinter at temperatures above 1000◦ C.
At this temperature, a silica core and a rare earth oxide shell can undergo a phase
transformation with an acentric site for rare earth substitutions. By controlling the
rare earths embedded in the silicate crystal lattice the particles X-ray luminescence
can be tailored towards different absorbers. The main focus of this work is to develop
a process that can isolate silicate core-shell nanoparticles, that when annealed, can
crystallize into a crystal structure which can scintillate. This non-toxic nanoscintillator would have the same size scale and have optical properties that can be optimized
towards different organic and biological moieties. In many biologically relevant applications it is essential that the phosphor is small enough to pass though biological
barriers (i.e. the blood brain barrier) while producing enough photons to excite its
conjugate. Typically this would require materials with high photon yields that are
approximately 100 nm or smaller as non-aggregated nanoparticles to be medically
relevant.
The combination of X-rays and sub-100 nm scintillators have gained interest in
the medical research for their deep tissue penetration and ability to generate luminescence that can couple to various biological conjugate. X-ray induced photodynamic
therapy and X-ray optogenetics are two techniques that have been created from the
growing popularity in scintillation research. These are relatively unexplored areas
in research and have a limited number of nanoparticles that have been exploited for
X-PDT and X-ray optogenetics. In the work that will be presented, a novel technique was developed and coin the high temperature multi-composite reactor. A multi
process technique that combines core-shell and composite synthesis of nanoparticles
that can be used to prevent irreversible aggregation of particulates above their sintering temperature. Two crystals will be explored in this work: 1) yttrium pyrosilicate
and 2) lutetium pyrosilicate, both of which were synthesized using a silica core, its
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respective rare earth oxide shell, and poly(divinylbenzene) as a sacrificial delamination layer. The optical luminescence can be tailored using different activators and
maximized using different doping strategies. In this work cerium, terbium, and europium will be investigated when embedded in an yttrium pyrosilicate particulate
and irradiated with Uv and X-rays. The last part of this work will focus on coupling
organic moieties on the nanoscintillators that have potential in biomedical theranostic
techniques. Three organic molecules will be investigated: 1) bovine serum albumin
(BSA), 2) indocyanine green dye (ICG), and 3) rose bengal (RB). In this work the
silica core and yttrium pyrosilicate shell particles were functionalized by copper azidealkyne cycloaddition click chemistry where the particles were modified with an azide
ligand and the organic molecules with and alkyne functional group.
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Chapter 2
A High Temperature
Multi-composite Reactor for
nanoscintillators
2.1

Introduction
X-rays brings an attractive aspect to medical theranostics for their insignificant

scattering in tissues and deep penetration depths. This has opened the possibilities of
deep tissue imaging with high spatial resolution and is the foundation for the uses of
X-rays in the medical community such as radiotherapy, computed tomography, and
fluoroscopy. The use of X-rays have been coupled with scintillating contrast agents
to generate new therapeutic and diagnostics tools such as X-ray luminescence optical
tomography (XLOT), X-ray excited optical luminescence (XEOL), and X-ray induced
photodynamic therapy (XPDT).
Nanotechnology in biology refers to cellular, molecular, and engineered materials which are distinguished by groups of atoms, molecules, and molecular frag29

ments. These nanoscale objects with dimensions of approximately 100 nm can travel
throughout the body where size-exclusion plays a role in their available sampling
space [103].The size-dependent permeability of the body can be exploited by material
designers to create systems that can readily interact either on the exterior or interior
of targeted biomolecules [104]. Radically new detection and treatment delivery systems have been developed over the last 35 years due to the access that these nanoscale
devices have to specific regions within the body [105, 106].
There have been a limited number of highly emissive non-hygroscopic and
non-toxic radioluminescent particles presented in the literature, though the cerium
doped lanthanide oxyorthosilicates and pyrosilicates are promising candidates [107–
109]. One common challenge in synthesizing radioluminescent nanoparticles of rare
earth silicates is the requirement of an annealing step at temperatures greater than
1000◦ C to achieve the reaction between the rare earth oxides and silica [110]. These
elevated temperatures will normally result in the sintering of the particles together
[111] and their irreversible aggregation, rendering them useless for biomedical applications [112].
A technique coined the high temperature multi-composite reactor (HTMcR)
process was developed which, is a general method for synthesizing radioluminescent
nanoparticles from cerium doped lanthanide pyrosilicates, though other chemistries
that require a high temperature annealing step may also benefit from the approach.
The HTMcR process is demonstrated by synthesizing nanoparticles composed of
cerium doped yttrium and lutetium pyrosilicates, YPS:Ce and LPS:Ce, respectively.
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(i) Scheme for the high temperature multi-composite reactor (HTMcR) process.
Initially, a silica (SiO2 ) core is over-coated with a rare earth oxide (RE2 O3 ) shell. This SiO2 /RE2 O3
core-shell particle is then surface modified with MPS to facilitate the attachment of an AIBN initiated polymerized DVB (pDVB) shell around the assembly before the SiO2 /RE2 O3 /pDVB particles
undergo an 1000◦ C annealing step in an inert atmosphere to convert the oxides to a radioluminescent
rare earth pyrosilicate (REPS) phase. During the annealing step, the organic pDVB shell carbonizes
to glassy carbon and frustrates particle to particle aggregation. After the RePS phase is formed, the
temperature is reduced to 800◦ C, a temperature where sintering is unlikely, and oxygen is introduced
into the chamber to remove the glassy carbon. (ii) TEM images of core-shell particles during the
various stages of the HTMcR process. (a) The initial SiO2 cores (122 ± 18 nm) are (b) over-coated
with yttrium hydrocarbonate doped with cerium (SiO2 /Y(HCO)3 :Ce) and oxidized at 750◦ C for 30
mins forming SiO2 /Y2 O3 :Ce particles (132 ± 21 nm). These latter particles are then (c) over-coated
with pDVB after being surface modified with MPS, resulting in SiO2 /Y2 O3 :Ce/pDVB (162 ± 26
nm). (d) The SiO2 /Y2 O3 :Ce/pDVB particles were carbonized in a nitrogen environment for 36
hrs at 1100◦ C to obtain SiO2 /YPS:Ce/Cglassy (147 ± 19 nm). (e) Finally, the glassy carbon is
removed by annealing at 800◦ C in air to obtain SiO2 /YPS:Ce (127 ± 17). Particle sizing based on a
population of 100 particles. Below each respective TEM images are the particles size (dc ) diameter
and the number of particles (N(dc )).
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2.2

Results and Discussion
The HTMcR is a multi step process with a core-bishell architecture with the

core and inner shell being a inorganic species while the outer shell being a cross
linked polymer that can carbonize into amorphous carbon. Figure 2.1i presents the
general HTMcR process which can produce radioluminescent silicate particles, with
its respective transmission electron microscopy images and particle size distribution
Figure 2.1ii of a silica core, Y2 O3 inner shell, and pDVB outer shell. The procedure
presented is general but was demonstrated with the rare earth species Y3+ , Lu3+ , and
Ce3+ . Initially, a base catalyzed Stöber process was employed to synthesize uniform
spherical silica particulates (122 ± 18 nm; cf. Figure 2.1ii(a)) [113]. Silica is often
employed as a passivation layer, a grafting agent platform, or a seed for core-shell
synthesis [114, 115], but in the HTMcR process, the silica core is repurposed as both
a structural template and chemical platform for the final nanoparticle. To that end,
a RE-hydrocarbonate (RE(HCO3 )3 ) is next precipitated onto the silica core by a seed
mediated growth technique [116]. The hydrocarbonate species on the silica cores were
then oxidized at 750◦ C according to

2RE(HCO3 )3

750◦ C

→

RE2 O3 + 3H2 O + CO2

(2.1)

to remove any water and/or carbon dioxide that may interfere with the HTMcR
process, resulting in a RE2 O3 shell on the particles (cf. Figure 2.1ii(b)).
To prevent aggregation at temperatures greater than 1000◦ C that are needed to
convert the oxide into a radioluminescent compound, a polymer coating is employed to
encapsulate the inorganic core-shell particle. To accomplish this polymer overcoating,
the SiO2 /RE2 O3 surface of the particles were modified with 3-(trimethoxysilyl)propyl
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methacrylate (MPS), which introduces alkene functionality onto the particle’s surface
that facilitates the adherence of an in situ created polymer coating [117, 118]. The
MPS-modified particles were redispersed in a solution containing acetonitrile, the
monomer divinylbenzene (DVB), and the free radical initiator azobisisobutyronitrile
(AIBN) and underwent a standard precipitation polymerization to coat the particles.
The polymerization of the bifunctional DVB around the particles, with the inclusion
of the surface attached MPS [119], results in an adherent cross-linked pDVB coating
on the particles (cf. Figure 2.1ii(c)) [120–122]. These SiO2 /RE2 O3 /pDVB particles
are then heated in an inert gas environment above 1000◦ C to convert the pDVB
into glassy carbon [123, 124]. Simultaneously during the heating cycle to convert
the pDVB to glassy carbon, the two oxides recrystallized to a rare earth pyrosilicate
(REPS) crystal:

RE2 O3 + 2SiO2

1000◦ C

→

RE2 Si2 O7 .

(2.2)

In the final step, the temperature of the system is lowered to 800◦ C and air is introduced into the chamber to remove the glassy carbon and generate unaggregated
radioluminescent nanoparticles.
Specifically focusing on cerium doped yttrium pyrosilicate Y2 Si2 O7 :Ce (YPS:Ce)
shell particles, the TEM image of the final SiO2 particles with a YPS:Ce shell is presented in Figure 2.3a. During the HTMcR process, on average, a 10.5 nm lanthanide
hydrocarbonate (Figure 2.2b) shell grew on top of the silica size template Figure
2.2a. Increasing the molar ratio of Y(HCO3 )3 /SiO2 have also been attempted however the resulting SiO2 /Y(HCO3 )3 particulates showed signs of 2 - 3 particulates
fusing above 200 nm. The upper limit of rare earth hydrocarbonate species that can
be deposited onto the silica surface while remaining monodisperse was 30 mol%. This
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would ultimately result in a pyrosilicate phase rather than the standard oxyorthosilicate phase. After annealing at 750◦ C for 30 mins, the hydrocarbonate species oxidized
and formed non-aggregated SiO2 /Y2 O3 :Ce particles with an average particle size of
132 ± 21 nm (cf. Figure 2.1ii(b)). The decrease in particle size (ca. 11 nm) can be
attributed to the loss of water, carbon dioxide, and densification. It was also observed
that the lanthanide shell had a darker contrast in TEM images. This could be due to
the heavier atomic elements reducing electron penetration through the particles. No
difference in size was observed when the SiO2 /Y2 O3 :Ce particles were modified with
MPS, however, the particles became hydrophobic due to the non-polar silane. pDVB
was successfully polymerized onto the surface of SiO2 /Y2 O3 :Ce with a shell thickness
of ca. 15 nm as seen by the triple contrast layer of the particles in Figure 2.1ii(c).
To form a YPS:Ce shell, during the conversion of the pDVB to glassy carbon, the
reaction temperature was set to 1100◦ C. After annealing in an inert environment
for 36 hours, the particles (SiO2 /YPS:Ce/Cglassy ) retained their spherical shape (cf.
Figure 2.1ii(d)) with an average particle size of 147 ± 19 nm (n=100). There is a
statistical significant 15 nm increase (p < 0.01) in the diameter (shell thickness ca. 7.5
nm) of the SiO2 /YPS:Ce/Cglassy particles compared to their SiO2 /Y2 O3 :Ce precursor
particles, indicating that the glassy carbon is present on the former particles.
The glassy carbon was removed at 800◦ C by introducing air into the chamber,
resulting in relatively monodisperse SiO2 /YPS:Ce (127 ± 17 nm) particles; Figure
2.3a presents a TEM image of the particles after being annealed for 36 hours at
1100◦ C using the HTMcR process. Figure 2.3b presents a field emission scanning
electron microscope (FE-SEM) image of a set of final SiO2 /YPS:Ce particles that
were annealed at 1100◦ C for 24 hours, while Figure 2.3c presents particles that
underwent the same procedure as the particles in Figure 2.3b except no pDVB was
used to coat the particles. Figure 2.4 compares different SEM images, at different
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Figure 2.2: (a) Silica nanoparticles (122 ± 18 nm) synthesized by the Stöber method and (b)
SiO2 overcoated with a Y(HCO3 )3 with an average particle size of 143 ± 20 nm.

(a)

100 nm

(b)

(c)

2000 nm

2000 nm

Figure 2.3: (a) SiO2 /YPS:Ce particles annealed at 1100◦ C for 36 hrs without any aggregation.
(b) A non-sintered agglomerate of SiO2 /YPS:Ce particles synthesized by the HTMcR process and
annealed for 24 hrs, while (c) the corresponding particles synthesized without pDVB and annealed
at the same conditions sintered to micron sized particles.
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(a)

(b)

(c)

(d)

(e)

(f )

(g)

(h)

Figure 2.4: (a-d) SEM images of SiO2 /YPS:Ce particles annealed at 1100◦ C for 1 hr without any
aggregation using the HTMcR method at different magnifications. (e-h) SEM images of irreversible
aggregation from the same set of particles annealed at 1100◦ C without using the HTMcR method

magnifications, of SiO2 /YPS:Ce particles which were annealed using the HTMcR
and annealed using a solid state approach for 1 hours at 1100◦ C. The particles in
Figure 2.3b & Figure 2.4a-d were not aggregated and exhibited a zeta potential
of ζ = -47.8 mV in deionized water, while the particles without the delamination
layer afforded by the glassy carbon sintered into large micron sized slabs. A zeta
potential with an absolute value greater than 30 mV is usually considered a signature
of a stable colloidal system [125]. In contrast, the particles of Figure 2.4e-h quickly
settled to the bottom when dispersed in water (Figure 2.5).
As indicated earlier the particle size of SiO2 /Y2 O3 :Ce is 132 nm, on average the
volume of the Y2 O3 :Ce shell encompasses 30% of the particles volume. After annealing
the particulate through the HTMcR process, the final particle has a interior silica shell
and YPS:Ce shell with a average particle size of 127 nm. The final SiO2 /YPS:Ce
particle has a YPS:Ce shell that accounts for 55% of the particle’s volume. The
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SiO2/Y2O3:Ce SiO2/Y2O3:Ce/ SiO2/YPS:Ce SiO2/YPS:Ce
Camorphous
with pDVB
without pDVB

Figure 2.5: (a) Different stages of the HTMcR particles dispersed in water and its respective
counterpart particle without the sacrificial delamination layer.

volume percent difference between the two stages of the particle’s would imply that the
YPS:Ce reached a densification of 87%. The overall volume shrinkage of the particle
during the HTMcR process can be attributed to many factors such as densification
of the silica core, recrystallization to the triclinic phase with a space group of P1̄
(cf. Figure 2.6), and loss of hydroxyls and gases in the pores of the particles In
addition, all particulates exhibited the same space group when annealed at 1100◦ C,
with diminishing growth in crystallite size after two hours of annealing (cf. inset of
Figure 2.6).
The elemental distribution spectroscopy (EDS) of the SiO2 /YPS:Ce particles
from scanning transmission electron microscopy in dark field indicated that cerium,
due to its low concentration in the particles, appears to be uniformly distributed
throughout the particle as indicated by the line scan of Figure 2.7, while, as expected,
the yttrium is concentrated in the shell of the particles [126, 127]. The Y/Si and
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Diffraction pattern of SiO2 /YPS:Ce particles annealed at 1100◦ C compared to a
lanthanide pyrosilicate single crystal (ICSD#171882). Inset is the calculated crystallite size of the
different annealed SiO2 /YPS:Ce particles.
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Figure 2.7: A qualitative approach to examine the elemental distribution in SiO2 /YPS:Ce particles annealed at 1100◦ C for 24 hrs. Scanning transmission electron microscope in dark field.
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Figure 2.8: EDS of inserted STEM images with characteristic X-rays of yttrium and cerium.
Representative spectra of Y/Si of 0.33 and Ce/Y of 0.9.

Ce/Y ratio in the final particles were 0.31 and 0.09, respectively (Figure 2.8). This
indicates that the rare earth species were fully incorporated onto the silica template
since these ratios are similar to the element ratios employed in the synthetic process
(0.30 and 0.08, respectively) and are within the 0.1% error of EDS.
The photoluminescence excitation (PLE) spectra of the dry SiO2 /YPS:Ce particles indicated three distinct peaks at 252 nm, 300 nm, and 341 nm when monitored
at 400 nm (cf. Figure 2.9a). The excitation peaks can be attributed to cerium’s
charge transfer and the transition from the 4 F7/2 and 4 F5/2 state to the 5d orbital
[128]. A singular photoluminescence (PL) peak at 400 nm was observed when the
particles were excited at 340 nm which can be attributed to the relaxation of electrons
in the 5d orbital to its F states [129]. In order to compare the total light output of
various nanoparticles, the integrated intensities of the PL spectrum were compared
between SiO2 /YPS:Ce particles annealed at 1100◦ C for different periods and is presented in Figure 2.9b. Based on the maximum integrated PL, the particles that
underwent a 24 hour annealing period were optimal. Extending the annealing period past 24 hours reduced the overall integrated luminescence and its hypothesized
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that a prolonged heating period may have (1) incorporated the glassy carbon into
the particles creating unintentional defect sites that act as traps for radiative energy
and/or (2) cerium oxidized from its active oxidation state (Ce3+ ) to its non-emitting
oxidation state (Ce4+ ) [130]. Comparing the optically and X-ray excited emission of
the particles indicates a slight red shift to ca. 427 nm with a low energy tail when the
SiO2 /YPS:Ce particles are excited by X-rays (cf. Figure 2.9a). This difference in
the two luminescence spectra could be attributed to the architecture of the core-shell
particles. Optical excitation energies can only penetrate the periphery of the particles
and the resulting emission is localized to a volume within the shell, while the X-ray
excitation has a deeper penetration depth. It is believed that this deep penetrating
excitation energy would influence the overall X-ray luminescence spectra of core-shell
nanoparticles. The silica core occupies 45% of the annealed nanoparticle’s volume
which was measured from the lighter contrast of the SiO2 /YPS:Ce TEM images.
Correspondingly, the deep penetrating X-rays used as an excitation source may have
excited both the YPS:Ce shell and the silica core, the latter having a X-ray luminescence peak at 450 nm [131]. This may have influenced the X-ray emission signature
of the core-shell nanoparticle when compared to an optical excitation, resulting in a
broad and combined X-ray luminescence of both YPS:Ce and silica.
The HTMcR process is a generalized methodology to produce scintillating
non-aggregated nanoparticles and this versatility was demonstrated by synthesizing
SiO2 /Lu2 Si2 O7 :Ce(LPS:Ce) nanoparticles in addition to the SiO2 /YPS:Ce particles.
Figure 2.10a presents SiO2 /LPS:Ce particles that were annealed at 1300◦ C for 1
hour. Similar to the SiO2 /YPS:Ce particles, the final SiO2 /LPS:Ce particles were
non-aggregated spheres with a diameter of 123 ± 14 nm and exhibited crystallinity
with lattice fringes of ca. 0.22 nm, indicated by Figure 2.10b. X-ray diffraction
spectra (cf. Figure 2.10c) of the particles indicated a conversion from a mixture of
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Figure 2.9: (a) PLE (λemit = 400 nm), PL (λexcite = 340 nm), and X-ray luminescence spectra
of SiO2 /YPS:Ce particles. (b) Integrated PL intensities (λexcite = 340 nm) of the nanocrystal with
annealing time at 1100◦ C.
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(b)

100 nm

Figure 2.10: (a.) SiO2 /LPS:Ce particles synthesized by the HTMcR process for 1 hr at 1300◦ C.
(b.) Crystallization of SiO2 /LPS:Ce particles with a lattice spacing of 0.22 nm at higher magnification. (c.) Phase transformation of SiO2 /LPS:Ce particles from the triclinic P1̄ to monoclinic C2/m
(ICSD#412249).

P1̄ and C2/m polymorphs to C2/m when the particles were annealed from 1100◦ C to
1300◦ C, respectively. It should also be noted that when the particulates were annealed
at 1300◦ the formation of amorphous carbon process was not always consistent. This
was visually observed by grey particulates after the high temperature carbonization
process. This problem may be mediated by using different and/or higher purity inert
gases such as argon or helium.
The SiO2 /LPS:Ce nanoparticles synthesized by the HTMcR process have a Xray emission spectrum with a peak at ca. 399 nm (cf. Figure 2.11). Published X-ray
and optically-excited emission spectra of bulk LPS:Ce crystals exhibit an asymmetric
emission profile with a dominate peak at 380 nm [132]. In low temperature opticallyexcited emissions, this asymmetry is clearly due to two emission peaks at 380 nm
and 415 nm, and is in agreement with the relaxation of the lowest 5d energy level
to the 2 F5/2 and 2 F7/2 states, respectively [133]. The discrepancy between the Xray emission of the SiO2 /LPS:Ce nanoparticles and its bulk counterpart is due to a
greater probability of electrons relaxing from the lower 5d energy level to the 2 F7/2
state based on the peak emission wavelength.
Both the SiO2 /LPS:Ce and SiO2 /YPS:Ce nanoparticles have scintillating properties that originate from the inclusion of cerium. Despite the similar synthetic route
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Figure 2.11: Radioluminescence of SiO2 /LPS:Ce particles.

for the two particles, the SiO2 /LPS:Ce X-ray emission is blue shifted relative to its
counterpart SiO2 /YPS:Ce. This could be attributed to the greater X-ray absorption
cross-section of the heavier atomic species lutetium where X-rays are primarily absorbed by the LPS:Ce shell [134] rather than the silica core, which has X-ray emission
peak at ca. 450 nm [131]. The efficiency of LPS:Ce to absorb X-ray photons compared
to YPS:Ce has been observed to increase light yield [135]. This greater efficiency to
absorb X-rays would result in a dominant LPS:Ce emission that overshadows the dim
silica’s x-ray emission.
These scintillating particles may find use in a range of novel bio-related applications, such as optogenetics, where the light emission for opsin modulation can be
achieved through radioluminescent nanoparticles [136] and the surface of the particles can be further modified with targeting moieties. To that end, cytotoxicity studies
were performed on both the SiO2 /YPS:Ce and SiO2 /LPS:Ce particles in human embryonic kidney 293T cells (HEK-293T)(Figure 2.12). For a 48 hour incubation time,
no change in cell growth relative to the control was observed with the SiO2 /YPS:Ce
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Figure 2.12: Cytotoxicity of (a) SiO2 /YPS:Ce and (b) SiO2 /LPS:Ce to a human embryonic kidney
cell (HEK-293) at different concentrations over 48 hrs.

and SiO2 /LPS:Ce nanoparticles at concentrations up to 7.31x105 and 5.42x105 particles per HEK-293T cell, respectively. Previous cell viability studies on monodisperse
100 nm amorphous silica nanoparticles indicated a 50% reduction in EAHY926 cell
viability (TC50 ) when silica particles were dosed at ca. 1x1012 particles per cm2 of cell
culture [30]. The maximum dosage of the SiO2 /YPS:Ce and SiO2 /LPS:Ce particles
were approximately 15% and 11%, respectively, of this TC50 value and indicated that
the particles do not exhibit any profound toxicity to the HEK-293T cells over 48
hours of incubation.

2.3

Conclusion
In summary, a high temperature multi-composite reactor (HTMcR) process

was successfully developed to isolate and recrystallize nanoparticles at temperatures
that would traditionally sinter these systems into large micron-sized monoliths. In
this example silica was used as a size and chemical template for SiO2 /YPS:Ce and
SiO2 /LPS:Ce. A annealing time study was applied to SiO2 /YPS:Ce to validate the
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HTMcR process and control the nanoparticles crystallite size. In this study the
HTMcR process was successfully able to prevent particles from sintering when annealed at 1100o C for up to 36 hours while its counter part sintered into micron sized
particulates. The SiO2 /LPS:Ce showed a conversion of its polymorph from P1̄ to
the C2/m space group when annealed from 1100o C - 1300o C, this experiment further
proves the versatility of the HTMcR process to anneal nanoparticles at temperatures
never before used in nanoparticle synthesis. Both crystals exhibited X-ray luminescence when doped with cerium with no toxicity observed in-vitro using HEK cells.
These findings indicates that the HTMcR process and the use of rare earth pyrosilicate nanoparticles are a promising avenue to use for biomedical application that
require scintillating properties.

2.4
2.4.1

Experimental
Materials and methods
All reagents were purchased from Alfa Aesar, Sigma Aldrich, and Acros Or-

ganics. Tetraethyl orthosilicate (TEOS) and 3-(Trimethoxysilyl)propyl methacrylate
(MPS) were distilled under vacuum. Divinyl benzene (DVB) was purified by passing
through a basic alumina oxide filter to remove the inhibitor. AIBN was recrystallized
from methanol. All other reagents were used without any purification.

2.4.2

Synthesis of silica core
Silica particles were synthesized by a modified Stöber process with TEOS

(67.18 mmol, 15.0 mL) dissolved in ethanol (150 mL), followed by addition of water
(15.0 mL) and then an aqueous solution of N H4 OH (29.38% v/v, 5.0 mL) was added
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dropwise. The reaction was stirred vigorously for 48 hours. Silica was then separated
and washed two times with water via centrifugation. A 95% yield of silica (3.8 g) was
obtained by evaporation of aliquots in the suspension. The silica particles (122 nm)
were dispersed in water (190 mL) for subsequent use.

2.4.3

Seed mediated growth of yttrium hydrocarbonate doped
with cerium on silica
The suspension of the silica spheres (16.64 mmol, 1.00 g) in water (500 mL) was

stirred vigorously. Yttrium nitrate hexahydrate (5.48 mmol, 2.10 g) and cerium nitrate hexahydrate (0.44 mmol, 0.19 g) was then added to the reaction vessel. Sodium
bicarbonate (16.67 mmol, 1.40 g) was dissolved in water (300 mL) and added dropwise
into the main reaction vessel at a rate of 2.5 mL/min. After the sodium bicarbonate
solution was fully incorporated, the reaction was stirred for an additional hour at
room temperature. The SiO2 /Y(HCO3 )3 :Ce particulates was separated and washed
two times with water via centrifugation. Once dried, the SiO2 /Y(HCO3 )3 :Ce particles was portioned for analytical characterization and further processing. A yield of
96% was obtained (2.52 g).

2.4.4

Oxidation of SiO2 /Y(HCO3 )3 :Ce
The SiO2 /Y(HCO3 )3 :Ce particulates were oxidized to form SiO2 /Y2 O3 :Ce at

750◦ C for 30 mins, with a mass loss of 26.5%.

2.4.5

Modification of SiO2 /Y2 O3 :Ce particles with MPS
The core-shell SiO2 /Y2 O3 :Ce particulates (1.20 g) was dispersed in 180 mL of

a mixed solution of methanol and water (9:1, v/v) with MPS (1.01 mmol, 0.24 mL)
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and ammonia hydroxide (1.68 mL). The reaction was mixed for 16 hours at room
temperature and then refluxed for 2 hours under vigorous stirring conditions. The
SiO2 /Y2 O3 :Ce/MPS particulates was washed two times in methanol via centrifugation.

2.4.6

Encapsulation of SiO2 /Y2 O3 :Ce particles with pDVB
The SiO2 /Y2 O3 :Ce/MPS particulates (1.00 g) was dispersed in solution of

acetonitrile (163 mL) with DVB (7.02 mmol, 1.00 mL) and AIBN (0.43 mmol, 0.07
g). The reaction vessel was degassed with N2 . Afterwards, the reaction vessel was
heated to 55◦ C for 20 hours. The reaction was allowed to cool to room temperature
and then washed two times with methanol via centrifugation.

2.4.7

High temperature annealing of SiO2 /Y2 O3 :Ce/pDVB
Once dried, portions of the SiO2 /Y2 O3 :Ce/pDVB particles was transferred to

a high temperature tube furnace, purged with nitrogen at a rate of 15 L/min for 20
mins, and annealed at 1100◦ C for varying time points. Afterwards, the black glassy
carbon from SiO2 /YPS:Ce/Cglassy particles was combusted at 800◦ C with a constant
flow of air at 15 L/min for 1 hour. The final particulates obtain was SiO2 /YPS:Ce.

2.4.8

Encapsulating and thermal treatment of SiO2 /Lu2 O3 :Ce
particles with pDVB
The synthesis of SiO2 /LPS:Ce particulates followed the same process as the

SiO2 /YPS:Ce particulates, with the exception of the annealing process where the
SiO2 /Lu2 O3 :Ce/pDVB particulates was annealed at various temperatures between
1100◦ C - 1300◦ C.
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2.4.9

Material characterization
A Hitachi 4800 field emission scanning electron microscope was used for FE-

SEM image acquisition, the particles were mounted onto a stub with double sided
carbon tape followed by plasma coating with platinum for 1 minute. A Hitachi 7600
TEM, Hitachi HT7830, and a Hitachi 2000 STEM was used to acquire TEM and EDS
maps of the particulates, all samples were dispersed in methanol and drop casted
onto a Formvar/Carbon 200 mesh TEM grid. RL of the different particulates were
excited by a Amptek Mini-X tungsten source operating at 25 kV and 158 µA. RL
measurements were taken in a free space environment where emitted light is directed
from a 2 inch concave mirror to a MicroHT (Horiba Jobin Yvon) monochromator and
a cooled synapse Horbia Jobin Yvon CCD detector with a grating of 300 mm and blaze
of 500 nm. Samples were packed in a 6.5 mm x 1.5 mm round flat washer on a quartz
slide. UV luminescence measurements were taken on a Jobin Yvon Fluorolog 3-222
spectrometer. The powder X-ray diffraction (pXRD) measurements were carried out
on a Rigaku Ultima IV diffractometer using CuKα radiation (λ = 1.5406 Å). The
powder diffraction data was recorded in 0.02◦ increments over a 2θ range of 5◦ to
65◦ at a scan speed of 1◦ /min. The crystallite size were calculated from the pXRD
data using the Scherrer equation. Experimental pXRD patterns were compared to
single crystal structures reported in the ICSD. Zeta potential was obtained using
Brookhaven ZetaPlus.

2.4.10

Cultured and MTS assay of human embryonic kidney
(HEK) cells

HEK-293T cells were obtained from American Type Culture Collection (CRL3216) and were cultured in Dulbecco’s modified eagle’s media (DMEM) containing
48

50 mL of heat inactivated fetal bovine serum and 5 mL of glutamine in a 500 mL
solution. Cells were cultured at 37◦ C in a humidified atmosphere of 95% air/5% CO2 .
The HEK cells were then plated in 96 well plates at a cell density of 4000 cells per well.
After the cells were plated for 24 hours, the cells were incubated with the different
particulates (SiO2 /YPS:Ce and SiO2 /LPS:Ce). For SiO2 /YPS:Ce, the concentrations
were 7.31x103 , 7.31x104 , and 7.31x105 particles per HEK cell. For SiO2 /LPS:Ce, the
concentrations were 5.42x103 , 5.42x104 , and 5.42x105 particles per HEK cell. At each
concentrations the cells were incubated for 24 and 48 hours. At the end of each
time point, the cell viability was measured using a [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium], inner salt (MTS) assay.
The media was removed and the plates were washed several times with phosphate
buffer solution before adding a solution containing 200 µL of DMEM media and 40
µL of MTS assay reagent. After 3 hours the absorbance was measured using a plate
reader at OD = 490 nm.
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Chapter 3
Energy transfer between cerium,
terbium and europium in a
SiO2/YPS particulate
3.1

Introduction
In the previous chapter a HTMcR was developed to synthesize refractory

nanoscintillators using a pyrosilicate host lattice and cerium as the luminescent activator. Two crystals explored previously were yttrium pyrosilicate and lutetium
pyrosilicate. While lutetium pyrosilicate would more efficiently absorb the X-ray
excitation energy this material is still inconsistent in carbonizing pDVB. As such yttrium pyrosilicate will be used as a model system to study energy transfer to enhance
X-ray luminescence. In this chapter the HTMcR technique was applied on the same
yttrium pyrosilicate host lattice with different mono-, co-, and tri-doped luminescent activators of cerium, terbium, and europium. The combination of these three
activators are of interest in down shifting luminescence because they can generate lu50

minescence throughout most of the visible spectrum which, is important for specific
absorption of biological conjugates in therapeutic. For example, in optogenetics different opsins have different absorption regions of wavelengths and selectively choosing
the right emitter is required for energy transfer from the luminescent particle to the
light sensitive protein (Figure 3.1a-c). Furthermore, if the nanoparticles are used
as an energy generator for theranostics a prominent spectral overlap is also needed
for the same reason. This chapter should serve as a guide on different strategies that
can be combined with the HTMcR to enhance the X-ray emission of cerium, terbium,
and europium.
The optical output of the donor is just as important as the spectral overlap
between the biological acceptor and nanoparticle’s emission. In the case of optogenetics it has been reported that the light intensity (measured in mW*mm−2 ) threshold
to activate a group of Channelrhodopsin-2 opsins is between 1-7 mW*mm−2 [140]. A
material’s challenge is reducing phosphors to the nanoscale while retaining it optical
output[141]. Since the surface to volume ratio increases with decreasing particle size,
the defects from the surface creates more emissive trap states reducing quantum yield
[142]. It has also been reported that crystallite size linearly influences the luminescence intensity and as such the upper limit of the crystallite size is limited to the
particle size [143]. The trade off between using sub-100 nm phosphors in biomedical
applications is its optical output. While the particle’s size is restricted from 50 - 200
nm the luminescent activators should be carefully chosen prior to the synthesis.
Different strategies have been developed to increase the optical output of nano
sized phosphors. One of the most common strategy is to introduce a sensitizer ion
to amplify low absorption activators in the excitation region used [144]. In this case
the sensitizer is introduced at a very low concentration, typically less than 1 mol.%
[145]. The sensitizer is able to absorb the excitation radiation and transfer its energy
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Figure 3.1: Spectral overlap between the emitters and absorbers of (a) cerium and ChR2 [137],
(b) terbium and Archaerhodopsin-3 [138], and (c) europium and a red-shifted variant of channelrhodopsin [139].
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through either a dipole-dipole, dipole-quadrupole, or quadrupole-quadrupole interaction to the luminescent ion [146]. In the case of cerium, its allowed 5d-4f transition
has a broadband absorption between 250 - 350 nm with a broadband emission that
ranges from 350 nm - 550 nm [147]. As such cerium is a suitable sensitizer to many
optically active lanthanide ions (i.e. Tb3+ , Dy3+ , Sm3+ )[148] with a longer excitation
wavelength requirement which is easier to generate and can couple to other luminescent activators through resonance energy transfer [149]. In this study the energy
transfer between cerium and terbium will be investigated to enhance the photo- and
X-ray luminescence of terbium with a maximum peak at 550 nm. This wavelength is
of interest as it can couple to many different biological conjugates such as the ArchT
opsin and RB a well known ROS generator[150].
Europium has been studied extensively in solid state lightening for its deep
red emission and ability to couple with other rare earth activators to generate white
emissions for LEDs. The current problem with this red emitting phosphors is the poor
energy efficiency when activated by UV radiation (300 - 400 nm). These shortcomings
arise from its absorption in the green region which cannot be solved with a single
sensitizer due to metal-metal charge transfer (i.e. Ce3+ + Eu3+ → Ce4+ + Eu2+ )
which ultimately quenches the sensitizer cerium [151]. In order to alleviate the metalmetal charge transfer a intermediary ion is introduced which is modeled as S → (I)n
→ A where S is the sensitizer with an allowed d-f transition, I the intermediary, and
A the activator with a forbidden f-f transition. In the case for cerium’s allowed d-f
transition and its energy transfer to europium’s forbidden 5 D0 → 7 Fn transition a
terbium bridge is introduced as follows Ce3+ → (Tb3+ )n → Eu3+ [152].
Figure 3.2 presents four different interactions that are possible between the
three dopants under UV excitation. When cerium absorbs the UV energy it can either
generate its respective emission or sensitize terbium [153]. In the second example
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terbium is the activator and a weak blue emission is generated from the 5 D3 →
7

Fj state [154]. Alternatively, multiple terbium ions interact with one another via

cross relaxation, where a green emission is generated from the 5 D4 → 7 Fj (j = 3-6)
transitions in terbium [155]. The last possible mechanism involves europium as the
activator and terbium that was either sensitized from cerium or cross relaxed with
another terbium ion. In this interaction terbium ions that are in close proximity with
a europium ion can flow its energy to Eu3+ and generate a red emission from the 7 Fj
→ 5 D0 transition [156]. The terbium ion not only acts as a pathway for different ions
to sensitize europium, but it also store the energy generated by cerium. Since cerium
is an allowed transition, its decay time is in the scale of nanoseconds. On the other
hand terbium is a f-f transition and has a decay time in the order of magnitude of
microseconds thereby allowing time for the europium ion to absorb terbium’s energy.
Another strategy to increase the optical output of luminescent nanoparticles is
to remove the surface sites where the luminescent ion can occupy with a passivation
layer. An activator on the surface is a unfavorable location due to the dangling bonds
and the occupation of hydroxyl groups. These defects creates surface quenching sites
that ultimately dissipates the photon’s energy [157]. Passivation layers have been of
interest to remove these dangling bonds and to facilitate the energy transfer between
the activators. This passivation layer is composed of the same crystal lattice without
a activator or a bioinert amorphous layer of silica. Numerous studies have shown both
types of passivation layer reduces luminescence quenching and increases its luminescence intensity relative to its non-passivated nanophosphor [158]. However, there is a
caveat when attempting to increase the photoluminescence of a nanophosphor with a
passivation layer. Ultra violet irradiation is only surface deep and if the passivation
shell is too thick the excitation energy will hamper the photoluminescence process
[159]. On the other hand, X-rays are fully penetrating and have the potential to be
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Figure 3.2: Branch model that depicts the energy transfer between, cerium, terbium, and europium. When exposed to a high energy radiation such as UV light cerium can either generate its
own emission or sensitize a terbium ion to generate a weak blue transition. The terbium ion that is
closest to the cerium ion also has two addition interactions. The first is to transfer its energy to a
neighboring terbium ion in its ground state through cross relaxation and generate a prominent green
emission or transfer its energy to a neighboring europium ion to generate a red emission. The last
possible interaction is that the terbium ion that was sensitized by another terbium ion can transfer
its energy to europium to generate europium’s emission
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absorbed by the inner luminescent sites of a particulate compared to Uv irradiation.
The X-ray luminescence spectrum of an extrinsic scintillator, a scintillator
that has a luminescent center that is doped, is dictated by its dopants. The spectrum
of rare earth f-f transition ions are unchanged when excited by X-rays or Uv irradiation. Additionally, the techniques discussed above have been applied to increase
scintillation of rare earth emitting phosphors. However, it is critical that the host
lattice constituent are composed of heavy elemental species which have high X-ray
stopping power to efficiently convert the absorbed X-rays into visible light [160]. The
scintillation mechanism from the host lattice constituent to the luminescent site can
be broken down into the following stages: 1) absorption of X-ray photons to excite
electrons in the conduction band and generate respective holes in valance band, 2)
relaxation of the primary electrons and holes to generate numerous secondary electrons and holes, 3) thermalization to of the electrons and holes to form e-h pairs with
energy equal to the band gap, 4) transport of the e-h pair to the luminescent center,
and 5) recombination of the e-h pair at the luminescent center to generate a visible
photon. The heavy elemental species of the host lattice enable its constituents to
sensitize the luminescent site. In the case of YPS and LPS, the (Si2 O7 )6− constituent
is a bioinert compound that suitable for biomedical applications and when coupled
with a heavy rare earth species can efficiently absorb incoming X-rays to generate
high photon yields [161].
This chapter will focus on optimizing the emission (excited by X-rays and
Uv radiation) of cerium, terbium, and europium doped in the yttrium pyrosilicate
lattice when synthesized by the HTMcR. The first part of the study will focus on
mono-doped system to obtain a baseline that will be used to compare the optical
output of the multi-doped systems. A co-doped system of cerium and terbium will
then be investigated where cerium is the sensitizer and terbium is the activator. The
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last system that will be discussed is a tri-doped system of cerium, terbium, and
europium. This study will look into a terbium bridge to reduce the metal-metal
charge transfer between cerium and europium. The nanoparticle’s luminescence is an
important factor that must be taken into consideration when looking at the spectral
overlap between itself and its biological conjugate. Another factor that must be taken
into consideration is the flux of photons generated by the nanophosphor such that the
optical output is high enough activate these light sensitive conjugates. However, trade
off between a materials size is its optical output due to the increase in defect sites
and surface from a nanomaterial. In the biomedical field it is essential that enough
photons are generated from the emitter such that energy can be transferred locally
to the biological absorbers. The HTMcR on multidoped systems offers a potential
solution to increase the photon yield of the emitting nanoparticles while remaining
at a size scale that is biomedically relevant.

3.2

Results and Discussion
YPS exhibits six different structures depending on the temperature and dop-

ing/stabilizing agents used during synthesis [162]. When employing the HTMcR to
a silica core and a cerium doped yttrium shell at 1100◦ C the particulates crystallize in the triclinic crystal structure with a P1̄ space group. In this structure the
cerium dopant can substitute at either the distorted trigonal or octahedral site of
Y 3+ , both of which are acentric, which increases the probability for the allowed d-f
electronic transition to occur [163]. In this report the active emitters are cerium,
terbium, and europium ions which have the same oxidation state as yttrium and will
substitute at the same acentric sites. No polymorphs of the various doped SiO2 /YPS
nanoparticles were observed during the crystallization process (Figure 3.3) and all
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products crystallized in the triclinic phase. All mono-, co-, and tri-doped particulates
were annealed at 1100◦ C for 18 hours with the highest doping concentration being
the tri-doped system at 30.75 mol% of yttrium. Furthermore, the consistent crystal
structure obtained at such a high concentration of cerium, terbium, and europium
would suggest that the YPS particulates can be doped with other rare earth emitters
and crystallize exclusively in the triclinic space group due to the similar size and oxidation state of the lanthanide series [164]. This has the potential to explore unique
optical properties that can only be observed by f-f transition.
All nanoparticles sets were synthesized by the HTMcR process. This enabled
use to prepare a variety of multidoped nanoparticles and convert them to the crystalline triclinc phase while maintaining the non-aggregated and well disperse nature
of nanoparticles. Transmission electron microscopy (TEM) shows the well dispersed,
cleanly doped nature of the nanoparticles with the various mono-, bi- and tridoped
silica core and yttrium pyrosilicate shell Figure 3.4 a-e. The dispersed spherical
nanoparticles would suggest that the HTMcR process does an excellent job in preventing irreversible aggregation at the elevated temperatures of the annealing conditions. The average particle size of YPS:Ce, YPS:Tb, YPS:Eu, YPS:Ce-Tb, and
YPS:Ce-Tb-Eu are all between 140 nm - 150 nm with no statistical difference between each sets. The similar final particle size is expected since the same silica core
was used throughout the different sets of particulates and is a size template for coreshell particles. A core-shell formation can be observed from all the particulates by
their contrast where, the dark contrast represents the heavier atomic elements composed of yttrium, cerium, terbium, and europium while the lighter contrast represents
the silica core. Interestingly, the YPS:Ce-Tb-Eu image presented has a particle with
a partial shell (Figure 3.4 e, i). Upon closer examination from electron dispersive
spectroscopy (EDS) the rare earth elements overlap with the dark contrast of the
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Figure 3.3: X-ray diffraction of different YPS particulates mono-doped with cerium (0.75%), terbium (10%), europium (15%), co-doped with cerium (0.75%) and terbium (10%), and tri-doped with
cerium (0.75%), terbium (15%), and europium (15%). All X-ray diffraction traces were compared
to a single crystal YPS crystal ICSD #171882.
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Figure 3.4: TEM of (a) YPS:Ce, (b) YPS:Tb, (c) YPS:Eu, (d) YPS:Ce-Tb, and (e) YPS:Ce-TbEu. EDS of YPS:Ce-Tb-Eu of (f ) silicon, (g) oxygen, and (h) yttrium. (i) SEM of YPS:Ce-Tb-Eu.
EDS of the rare earth emitters in YPS:Ce-Tb-Eu of (j) cerium, (k) europium, and (l) terbium.

transmission electron microscopy image further supporting the postulate of core-shell
formation (Figure 3.4 f-h, j-l). The elemental mapping demonstrates that yttrium,
cerium, terbium, and europium are uniformly distributed throughout the shell.
Three mono-doped lanthanides were explored in the yttrium pyrosilicate crystal lattice synthesized by the HTMcR, the first of which is cerium, followed by terbium, and lastly europium. Figure 3.5 presents the optical and X-ray luminescence
of mono-doped Ce3+ , Tb3+ , and Eu3+ in the SiO2 /YPS particulates. When doped
with cerium, the optical and X-ray luminescence properties exhibit the same d-f transitions previously reported, where a slight red shift is observed due to the silica core’s
X-ray luminescence [165]. For photoluminescence, both the terbium and europium
doped particulates were excited at their optimal excitation wavelength at 250 nm.
Terbium doped SiO2 /YPS particulates exhibits four luminescence peaks at 493 nm,
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542 nm, 590 nm, and 623 nm corresponding to the electron relaxation from 5 D4 state
to the 7 F6 , 7 F5 , 7 F4 , and 7 F3 states respectively[154]. The mono-doped europium system has four peak regions at 580-600 nm, 610-620 nm, 650-660 nm, and 690-700 nm
which are ascribed to the relaxation of electrons from the 5 D0 state to the 7 F1 , 7 F2 ,
7

F3 , 7 F4 states, respectively[166]. Notably both terbium and europium doped systems

have matching photoluminescence and X-ray luminescence while, cerium has a red
shifted X-ray luminescence. This can be attributed to the f-f transitions of terbium
and europium whereas cerium is a d-f transition which is influenced by the crystal lattice and the defects inherent to nanophosphor resulting in the mixture of silica’s and
cerium’s radioluminescence. The combination of these dopants can be strategically
decided during synthesis to potentially couple its X-ray luminescence with potential
biological conjugates. In optogenetics the chosen light sensitive proteins will only
respond to specific wavelengths of photons. For example, channelrhodopsin-2 has
the potential to absorb the emission from SiO2 /YPS:Ce while a red-activatable channelrhodopsin can absorb the emission of SiO2 /YPS:Eu due to the spectral overlap
between the particulate’s emission and the protein’s absorption [96].
Maximizing the spectral overlap offers the potential to couple specific phosphors with appropriate biological conjugates however sufficient energy needs to be
supplied from the emitter that can elicit a response form the absorber. The simplest
method to increase the light output of doped inorganic phosphors is by controlling
the dopant concentration and by multi-doping the system. In this report three different concentrations of terbium and europium were investigated as a baseline to then
optimize the multi-doped system that have been reported to enhance the photoluminescence of inorganic phosphors. Figure 3.6 presents both photoluminescence (excited at 250 nm) and X-ray luminescence of SiO2 /YPS:Tb and SiO2 /YPS:Eu doped
at different concentration relative to yttrium. Terbium was doped at 1, 3 and, 10
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Figure 3.5: PLE, PL, and RL of SiO2 /YPS mono-doped with (a) Ce3+ , (b) Tb3+ , and (c) Eu3+ .
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mol% while europium was doped at 1, 10 and 15 mol%. No spectral shifts or luminescence quenching were observed throughout the study. For the mono-doped system
of terbium the integrated intensity of both radio- and photoluminescence (excited at
250 nm) increased linearly with doping concentration suggesting a overall increase
in its optical light output. Not surprisingly terbium did not absorb the excitation
energy at 338 nm which, is the same excitation energy that is optimally absorbed
by cerium. Europium on the other hand have multiple excitation bands between 250
nm - 550 nm with a emission spectrum with noticeable integrated intensity when
excited at both 338 nm and 250 nm. Interestingly, YPS:Eu doped at 10 mol% and
15 mol% showed no difference in its optical output in its photoluminescence when
excited at 250 nm. However, the X-ray luminescence of the europium doped system increased its light output linearly with europium concentration. The results
from SiO2 /YPS:Eu can be explained by the experimental setup in which, broadband
bremsstrahlung X-rays were used and this high energy excitation source will excite
the electrons from the valence band as well as the electrons in core band increasing
the probability for a exciton to form. A comparative X-ray luminescence study was
performed on SiO2 /YPS:Eu (15%) and SiO2 /YPS:Ce to commercial micron sized europium doped gadolinium oxysulfide and YSO:Ce, respectively. The SiO2 /YPS:Eu
nanoparticles had a integrated intensity that was 4% to gadolinium oxysulfide doped
with europium while the prolonged acquisition time of SiO2 /YPS:Ce would exceed
the capabilities of the detector to measure YSO:Ce light output. This lower light output of the SiO2 /YPS particulates are expected since nanomaterials have inherently
more surface and defects compared to it’s bulk counterpart. This would present trap
states that would diminish its emission. However the size scale of the nanomaterials
cannot be changed if it is to couple with biological conjugates. The trade-off between
the size of a nanophosphor is its optical output, however enough photons needs to be
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Figure 3.6: (a) PL (excited at 338 nm) and (b) RL of SiO2 /YPS:Tb when doped at 1, 3 and
10 mol% of terbium. (c) Optical output of SiO2 /YPS:Tb when excited by Uv radiation at 250 nm,
338 nm, and X-rays. (d) Photoluminescence (excited at 338 nm) and (e) Radioluminescence of
SiO2 /YPS:Eu when doped at 1, 10 and 15 mol% of europium. (f ) Optical output of SiO2 /YPS:Eu
when excited by Uv radiation at 250 nm, 338 nm, and X-rays.

generated to couple with biological absorbers. In such a case it is paramount that
energy transfer mechanisms are investigated to enhance the emission of the differently
doped SiO2 /YPS particulate’s.
Initially the photoluminescence of SiO2 /YPS mono-doped with terbium was
compared to its co-doped counterpart with cerium and terbium Figure 3.7. When
irradiated at 338 nm the mono-doped terbium system generates no significant emission however, the co-doped system with has a mixture of cerium’s and terbium’s
emission which, would suggest energy transfer is present between the two dopants.
Furthermore, when the terbium’s concentration is increased cerium’s emission begins
to decrease while the terbium’s emission increases. The energy transfer efficiency
from the sensitizer to the activator can be quantified by the following equation [146]:
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η =1−

I
Io

(3.1)

Where η is the energy transfer efficiency of the sensitizer to activator, I is
peak emission intensity of the sensitizer with activator and Io is the emission intensity
without the activator. In order to study energy transfer between Ce3+ and Tb3+ four
concentrations of terbium were selected (1%, 3%, 5%, and 10% relative to yttrium)
while cerium was kept at a constant concentration at 0.75% relative to yttrium. The η
of the co-doped system was measured when excited at 250 nm and 338 nm, saturating
at 90% and 65%, respectively. The Tb3+ emission dominates when the co-doped
SiO2 /YPS particulates were excited by X-rays. The radioluminescence integrated
intensity of the co-doped system exceeded the mono-doped Tb3+ series. This suggests
that energy transfer is still occurring under X-ray excitation and enhances the overall
light output of sub-100 nm particles. The highest light output observed between the
four samples was a concentration of 0.75% cerium and 3% of terbium. The dominant
energy transfer pathways can be suggested in Figure 3.7e by the following: 1)
electrons from Ce3+ ground state is excited to the 5d orbitals, 2) some of the electrons
relax to its respective lower energy state of cerium emitting a broad band from 350 500 nm with a peak at 400 nm while some of the electrons transfer its energy from the
5d orbitals to the 5 D3 state of Tb3+ through dipole-quadrupole interactions, 3) the
excited electrons in the 5 D3 nonradiative decays to the 5 D4 state and relaxes to the
ground states of Tb3+ (7 F3,4,5,6 ) giving a strong green emission with bands peaking
at 485 nm, 550 nm, 590 nm, and 625 nm.
The presence of Tb3+ in a tri-doped system of Ce3+ and Eu3+ creates an ionbridge where cerium acts as a sensitizer for terbium which can then transfer energy
to europium [167]. The photoluminescence of the cerium-europium co-doped system
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Figure 3.7: (a) PL of SiO2 /YPS mono-doped with Tb3+ compared to a co-doped system. (b)
Quantum efficiency of the co-doped system when excited at 338 nm and 250 nm. (c) RL of the
co-doped system and its (d) integrated intensity when compared to mono-doped SiO2 /YPS:Tb. (e)
Energy transfer from cerium to terbium.

is compared to a cerium-terbium-europium tri-doped system Figure 3.8a. When
excited at 338 nm the co-doped system only has a cerium photoluminescence band
where the emission diminishes due to metal-metal charge transfer between cerium and
europium (Ce3+ + Eu3+ → Ce4+ + Eu2+ ) where Ce4+ is non-radiative. Once terbium
is introduced the metal-metal charge transfer is reduced by a cerium to terbium energy
transfer, a phenomenon that was previously seen to effectively enhance the emission
of terbium. In this event, terbium acts as a sensitizer for europium allowing some
of energy of the terbium excited state to leak into the europium ion. This results in
a broadband emission that span the majority of the visible spectrum from 350 nm
- 700 nm form the initial 338 nm irradiation. Introducing a greater concentration
of terbium reduces the ion-ion distances allowing terbium to cross relax with one
another and making it more efficient to transfer its energy to europium as suggest by
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the decrease in the cerium and terbium bands and a increase in the europium bands.
Under X-ray excitation the tri-doped system showed a slight emission at 550 nm,
which is where terbium can emit, along with two dominant europium bands at 600
nm and 680 nm (Figure 3.8b). When the RL integrated intensity of YPS:Ce-Tb-Eu
was compared to YPS:Eu at 15 mol% an initial decrease in output was observed with
a 1 mol% of terbium followed by a overall increase in its optical output at 10 mol%
and 15 mol% (Figure 3.8a). The RL optical output is three time greater than the
SiO2 /YPS:Eu 15 mol% mono-doped system, which suggests that the terbium bridge
transfers energy from cerium and terbium to europium. The four possible interactions
to explain the photoluminescence are: 1) cerium absorbs the Uv irradiation and
generates emission, 2) excited state cerium transfer energy to terbium and causes a
green emission, 3) a terbium ion is in close proximity with a neighboring terbium
ion and cross relaxes to emit it’s own emission or transfer to europium which would
emit a photon corresponding to europium emission, and 4) europium absorbs the
incoming irradiation and emits. The resulting spectrum would be a broad emission
with characteristics of cerium, terbium and europium. When compared to the RL of
SiO2 /YPS:Ce-Tb-Eu however, the dominant bands are from europium with a only
negligible band from terbium and no cerium emission was observed. This would
suggest that the deep penetrating X-ray excitation source is exciting the inner rare
earth ions of the particulate increasing the energy transfer efficiency of europium.
This also implies that the use of opsins that are optimized for europium emission
absorption would be the more efficient biological and optogenetic performers.
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Figure 3.8: (a) PL SiO2 /YPS tri-doped with Ce3+ , Tb3+ , and Eu3+ . (b) RL of the tri-doped
SiO2 /YPS series and its respective (c) integrated intensity values compared to the brightest monodoped SiO2 /YPS:Eu (15%). (e) Energy transfer scheme from cerium to terbium to europium.
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3.3

Conclusion
The optical and X-ray luminescence of cerium, terbium, and europium were ex-

plored in a yttrium pyrosilicate nanoparticle synthesized by the HTMcR. Terbium and
europium were mono-doped at three different concentrations and had the highest light
output under UV and X-ray excitation at 10 mol% and 15 mol% respectively. When
cerium and terbium were co-doped into the host lattice, cerium became the sensitizer
for terbium. When the nanoparticles were excited at 338 nm, the co-doped series
exhibited luminescence with both cerium and terbium characteristics and increased
X-ray luminescence compared to the mono-doped series. Optimal X-ray luminescence
concentration from the co-doped series was determined to be 0.75 mol% cerium and
3 mol% of terbium. The tri-doped series explored the ion-ion distances of terbium
where cerium was the sensitizer and europium the activator. Under UV excitation
the tri-doped series exhibited photoluminescence at 338 nm and 250 nm. When these
particles were excited at 338 nm, the photoluminescence span the majority of the
visible spectrum with distinguishable peak of cerium, terbium and europium. When
excited at 250 nm the photoluminescence exhibited a dominant europium emission.
The X-ray emissions of the tri-doped series showed only europium characteristics with
enhanced light output when the terbium-terbium distance was reduced at 10 mol%
and 15 mol%. While the work provided here focused on the SiO2 /YPS nanoparticles,
the same co- and tridoping strategies can be applied to higher atomic number particulates such as SiO2 /LPS. These multidoped nanoparticles synthesized by the HTMcR
have the ideal size and X-ray luminescence that are compatible with a diverse range
of biological absorbers such as opsins for optogenetics.
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3.4

Experimental
All sets of particulates were synthesized using the same methodology as in

chapter 2 with the exception that higher concentration of the activators were substituted relative to the yttrium content. The same experimental set up in chapter
2 was used to obtain photoluminescence excitation, photoluminescence, and X-ray
luminescence. Electron micrographs and elemental mapping were obtained using
a combination of Hitachi HR-TEM 9500, Hitachi UHR-TEM 9000, Hitachi STEM
HD2000, and Hitachi TEM-HT7830.
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Chapter 4
Biofunctionalization of SiO2/YPS
particulates through copper
azide-alkyne cycloaddition
4.1

Introduction
In the past 30 years a plethora of nanoparticles with multiple functionalities

have gain popularity in the biomedical field for their versatility such as multi-modal
imaging, enhanced therapeutic, and theranostics. As the trend from research extends
to applications a single component nanoparticle is too simple to satisfy complex requirements. In the biomedical field this complexity can span from an imaging probe
and a vehicle for drug delivery or multi modal imaging that can combine optical,
ultra sound, magnetic, and/or X-ray imaging. Six functions can be obtained from
nanomaterials and are applicable for medical applications [48]: 1) signal generation,
2) independent signal generation, 3) energy conversion, 4) drug delivery, 5) targeting/guiding, and 6) catalytic activity. In signal generation a external source is used
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to excite the nanoparticle and generate the desired signal; this is commonly seen in
magnetic resonance imaging, florescence imaging, and ultrasound imaging. Independent imaging on the other hand is when the nanomaterial does not require a external
source and self-generates its own electromagnetic wave such as radioactive tracer used
in positron emission tomography. Energy conversion is when the energy generated by
the nanomaterial is converted into heat or another chemical reaction to purposefully
damage tissues such as photothermal therapy and photodynamic therapy. The high
surface area of nanoparticles can also be loaded with drug molecules and be released
in a controlled manner to enhance therapeutics. When grafted with specific targeting
agents these nanomaterials can also bind to malign cells or tissues for therapeutics
and imaging. Lastly, nanomaterials can act as catalytic sites to generate reactive
oxygen species or promote oxygen evolution reactions that are concurrent with photodynamic therapy. The ideal nanoparticle system for medical applications would
incorporate two or more of these capabilities in a single platform.
One approach to produce multifunctional nanoparticle is by controlling the
material’s structure such as a core-shell architecture. This heterostructure takes advantage of two materials with different properties and combines it into a single platform. One example of this structure is a hydrophobic iron oxide core for its magnetic
properties and a fluorophore for its luminescent properties such as ICG in IR imaging
[168]. The inorganic-organic hybrid materials are the preferred structure for biomedical application due to its versatility and have been implemented in gene therapy,
drug delivery, and theranostics [169]. For biomedical applications involving X-rays,
the inorganic building block can efficiently absorb the high energy radiation with its
large effective atomic number, while the organic ligand can improve the particulates
biodistribution and luminescence. The core-shell structure can also be applied to
inorganic-inorganic structures such as erbium and ytterbium co-doped in a NaYF4
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lattice for upconversion luminescence and a NaGdF4 shell as a T1 MRI contrast agent
[170]. In this structure the Gd3+ enhances the T1 contrast and the upconversion luminescence by removing the NaYF4 surface sites making it the standard practice in
this particle imaging technique [171]. However, many inorganic-inorganic compound
will still have some organic coating to improve biocompatibility. In this chapter a
SiO2 /YPS inorganic core and a organic coating will be explored as this structure
is the most versatile method to synthesize multifunctional nanoparticles due to the
breadth of biocompatible organic molecules.
CuAAC click chemistry is a popular method to engineer nanoparticles with
multiple functionalities. This reaction occurs when an organic moiety with a alkyne
functional group and a terminal azide group is in the presence of Cu(I) to form a
1,4-disubstituted-1,2,3 triazole as seen in Figure 4.1. In comparison to other noncatalyzed click chemistry the process does not form regioisomers and is 107 faster
allowing this reaction to occur at room temperature [172]. Three key steps have been
universally accepted for this process: 1) a 5-triazolyl copper intermediate is formed,
2) the nucleophilic carbon on the Cu(I) interacts with the electrophilic nitrogen on
the azide, and 3) the metallocycle undergoes ring contraction and dissociation to
regenerate the catalyst [173]. CuAAC is a user friendly reaction that can occur in
many aprotic and protic solvent including water [174]. This allows various organic
molecules with different solubility to be clicked onto the particulate [175]. Furthermore, this reaction has a high tolerance to other species with different functional
group without contamination allowing multi-click reactions to occur [176]. Lastly,
this reaction requires cuprous slats to initiate this reaction. While Cu(I) is the most
unstable oxidation state for copper, CuAAC can still occur when cuprous ions are
produced in-situ. Therefore, Cu(II)salts can be reduced with a reductant such as
sodium ascorbate. While the prospect of using CuAAC to add diverse functionalities
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onto nanophosphors is promising a potential drawback is the toxicity of using a Cu(I)
catalyst. A low concentration (10µM) of copper can kill cells, however during the
synthesis reports of chelated Cu(I) ions can reduce cytotoxicity [177]. The high tolerance and diverse set of organic moieties of CuAAC makes this reaction a powerful
toolbox to design multifunctional materials that can leverage the ability of both the
nanoparticle and the organic ligands.

Figure 4.1: Copper-catalyzed azide-alkyne cycloaddition mechanism.

Cytotoxicity of nanoparticles is a common concern that all materials research
in the biomedical field look into. The combination of CuAAC and serum albumin
can be used to reduce toxicity between particle-cell interactions. Two common serum
albumin used in materials research are human serum albumin and BSA. Both of these
proteins have the ability to interact with a wide variety of fluorophores, endogenous,
and exogenous ligands [178]. Serum albumin is a complex structure with 580 amino
acids characterized by three major domains (I, II, III) and each major domain have
2 subdomains (IAB, IC, IIAB, IIC, IIIAB, IIIC) [179]. These subdomains share
common traits such as hydrophobic faces where different ligands such as dyes, fatty
acids, and drugs can bind to [180]. In the case of organic fluorophores bonded onto
a nanophosphor, two strategies can be employed with serum albumin: 1) the surface
modified nanoparticle naturally interacts with the abundance of serum albumin in
blood or 2) a alkyne modified N-Hydroxysuccinimide reaction can be performed to
introduce a alkyne functional group to the protein, followed by a one pot CuAAC
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click chemistry with a azide modified organic fluorophore, alkyne modified serum
albumin, and azide functionalized nanoparticles. Both strategies have trade-offs when
employed. The first has the highest potential grafting density of fluorophores onto
the phosphors surface however the protein-particle interaction can be inconsistent
and determined by probability. The second method limits the number of dyes that
can bind onto the particles with consistent dye-protein interaction. In the second
method, when BSA is modified with alkyne there are 40 possible binding sites for
dyes or to be clicked onto the particle [181]. However, it has been reported that
the luminescence of a organic dye can be enhanced when it is sequestered inside the
hydrophobic pockets of BSA; furthermore this protein-dye interaction can generate
luminescence in aqueous environments of conventional non-luminescent hydrophobic
dyes [182]. Serum albumin is a common protein that is ubiquitous in blood which
can be used to reduce cytotoxicity and enhance dye emissions when clicked onto a
nanoparticle.
ICG is a U.S. Food and Drug approved tricarbocyanine fluorescent dye with
a strong absorption at 780 nm and near infrared emission between 825 nm - 900 nm
[183]. This emission minimizes tissue’s autofluorescence and is optically transparent
to hemoglobin. As a biological marker this compound has been used to guide surgery,
sentinel lymph node biopsy, and blood flow measurements [184]. However, this dye
is susceptible to photobleaching in a aqueous environment and binds to unspecific
proteins such as albumins [185]. Two strategies have been employed to increase the
stability of ICG: 1) grafting ICG on nanoparticles to reduce self aggregation when
illuminated by a laser and 2) encapsulating the dye in a biologically inert matrix (i.e
silica or poly(lactic-co-glycolic acid)) to isolate ICG from biological conditions [186].
As the research in ICG grew its platform extended from imaging to therapeutics in
photothermal therapy due to its acceptable photothermal conversion and approval
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from the FDA. By chemically altering ICG with biological peptides such as RGD this
dye can bind to specific receptors on the cell membrane such as αv β3 which is over
expressed on tumor endothelial cells [187]. ICG is a florescent dye that has promising
uses in imaging and photothermal therapy due to near infrared emission to penetrate
epidermis cells and photothermal conversion, however this dye requires alterations to
increase its stability and targeting of specific cells.
RB is a halogen xanthene dye that has a strong absorption band between 480
nm - 550 nm and can efficiently produce singlet oxygen (φ = 1 O2 = 0.75 under 540
nm irradiation) in a aqueous environment[188]. As such RB has been extensively
studied as a photosensitizer for PDT and X-PDT [189]. However, RB is hydrophilic
and thus has poor intercellular uptake [190]. A X-ray transducer in the form of a
nanoscintillator is needed to generate the specific wavelength of light for RB to absorb
since visible/infrared light is readily absorbed by dermal tissue [191]. Furthermore,
the nanoparticle acts as a vehicle that can be used to enhance the uptake of RB when
grafted on its surface. Similar to resonance energy transfer, the sub-100 nm scintillator is engineered with the photosensitizer RB and potentially other biologically
compatible ligands to reduce toxicity and target specific cells. When irradiated with
X-rays, the scintillator can produce luminescence at 550 nm that can effective be
absorbed by RB. In combination with radiotherapy (the use of a high energy source
that can pinpoint a location and destroy/shrink cancer cells), RB can break the oxygen and water molecules into their respective radicals and kill cancer cells [192]. In
combination with the high tissue penetration depth of X-rays and a transducer in
the form a nanoscintillator, the photosensitizer RB has the potential to target cancer
cells that are too difficult to reach through surgical practice.
PDT is a minimally invasive technique that requires a photosensitizer which,
when exposed to a specific wavelength of light and in the presence of oxygen (i.e H2 O
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or O2 ) can generate ROS that can be localized to kill cancer cells [193]. PDT requires a
high degree of particle engineering where a nanophosphor acts as a transducer that can
generate light when radiated by an energy source (infrared for PDT), a photosensitizer
that can absorb the incoming light from the phosphor, and other organic moieties that
can assist with targeting and/or enhancement in light generation [82]. In a laboratory
setting, near infrared fluoride nanoparticles doped with rare earths (NaYF4 , NaF, KF,
GdOF) are commonly used as the transducer [194]. Organic moieties that can absorb
the light emitted by the transducer are used as the photosensitizers which can be
in a form of a synthetic dye, tetrapyrrole backbone structure, or natural products
[195]. Clinically, this technique has seen success for early development and surface
deep cancer treatment [196]. However this treatment option is limited by its lack of
tissue penetration in the visible light spectrum and near infrared approaches can only
penetrate millimeters through the skin [197].
An alternative approach being research that can alleviate the shallow penetration depth of PDT is X-PDT in which the weak infrared excitation source is replaced
with deep tissue penetrating X-rays [81]. Furthermore, the transducer is replaced
with a sub-100 nm scintillator, a materials that can convert high energy radiation
(i.e X-rays, γ-rays, etc.) into light [198]. This therapeutic technique broadly, has
the same cascading effect as PDT from the excitation source, to the transducer, and
lastly to the photosensitizer in order to generate ROS [199]. Additionally, the localized X-rays are also used as radiotherapy in conjunction with X-PDT to kill cancer
cells [200]. X-PDT can also generate two potential ROS called type 1 ROS and type 2
ROS. Type 1 ROS is created when X-rays interacts with a cell membrane or molecule
and the transfer of electron forms a radical which can then form oxygenated products,
while type 2 ROS is formed by direct energy transfer to convert a triplet oxygen to
a singlet oxygen [12]. In both events the ROS generated is cytotoxic to cancer cells
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and its respective metastasis for whole body metastasis control.
An added benefit that X-PDT offers, that traditional infrared PDT cannot,
is the limitless emission from the transducer that can be used. PDT has a limited
spectral window in which it can operate efficiently, in this case the photosensitizer is
hampered by a absorption range between 650 nm - 800 nm since Uv and visible light
would be absorbed by the skin and above 800 nm is insufficient energy to produce
the singlet oxygen species [201]. X-PDT on the other hand can take advantage of
the various scintillators that can generate different radioluminescence locally to a
photosensitizer and undergo FRET [202, 203]. This would remove the limited spectral
range to generate singlet oxygen species and would only require a well engineered
particle system. Two factors would be considered for this particle: 1) the transducer
in the form of a scintillator and 2) the photosensitizer that can generate ROS both of
which would need to have a high degree of spectral overlap for energy transfer to occur
[204]. The ideal scintillator for X-PDT would have a high atomic number for high
X-ray stopping power, have a high light output for efficient energy transfer, size small
enough for endocytosis, and non-toxic to humans [205]. The photosensitizer should
have a high triplet quantum yield that would result in a high ROS generation when
it absorbs the incoming energy from the scintillator [206]. While there are numerous
photosensitizer that have been discovered for X-PDT there are still a limited number
of scintillators for X-PDT due to the difficulty in its synthesize while retaining its
size and conversion efficiency. However, it has been previously demonstrated that
SiO2 /YPS nanoparticles can be successfully synthesized by the HTMcR which can
be doped with cerium and terbium and have X-ray luminescence that can optically
couple to RB and generate ROS (Figure 4.2).
The work presented here demonstrates that particulates synthesized by the
HTMcR can be modified with different functional groups for CuAAC that have unique
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Figure 4.2: Scheme of SiO2 /YPS:Ce-Tb bonded with RB via click chemistry for X-PDT.

X-ray luminescence properties for biomedical application that have not been explored
before. First the particulates were modified with either a azide or a alkyne functional
group to increase its versatility in CuAAC. Afterwards three organic moieties were
explored. The first organic moiety was BSA for its high cell affinity, then ICG for its
potential as a IR tracer, and lastly RB for X-PDT.

4.2

Results and Discussion
(3-azidopropyl)trimethoxysilane was bonded to the surface of SiO2 /YPS:Ce

under reflux conditions and confirmed using Fourier transmission infrared spectroscopy
as seen by its 2100 cm−1 absorption, a signature IR peak for the azide structure (Figure 4.3a). A unmodified SiO2 /YPS:Ce was used as a comparison where no absorption
in this range was detected. Bovine serum albumin was modified with alkyne functional group using a N-hydroxysuccinimide reaction. At 28◦ C the nanoparticles and
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Figure 4.3: (a) FTIR of SiO2 /YPS and FTIR of SiO2 /YPS functionalized with az-sil. The peak
at 2100 cm−1 supports the successful binding of the azide ligand (b) TEM image of SiO2 /YPS
coated with BSA proteins after CuAAC. The triple layers seen in the image are suggested to be
silica, YPS, and BSA. (c) TEM image of Sio2 /YPS/PA.

protein were reacted with Cu(II)sulfate pentahydrate and sodium adsorbate. The
sodium adsorbate reduces the Cu(II) into Cu(I) and therefore created the catalyst
for CuAAC. TEM of the SiO2 /YPS:Ce/BSA particulates confirmed a bilayer shell
of the inorganic SiO2 /YPS:Ce and a 5 nm shell of BSA (Figure 4.3b). A alternative CuAAC approach is also presented in (Figure 4.3c) where SiO2 /YPS:Ce was
polymerized with propargyl acrylate and formed a silica core, a YPS shell, and a
poly(propargyl acrylate)shell. In this system the particulates are overcoated with an
alkyne functional group to allow organic molecules with azide functional groups to be
bonded. Two avenues are presented for CuAAC, where the SiO2 /YPS:Ce particulates
can be functionalized either with a azide group or a alkyne group.
As previously stated ICG is a FDA approved dye that can be used as a IR
tracer and the potential to be applied in photothermal therapy. When coupled to a
scintillator, this dye has the potential to be X-ray excitable via FRET between the
particulate and dye. Furthermore, BSA have also been reported to enhance the luminescence of hydrophobic dyes. This hybrid system will be composed of SiO2 /YPS:Ce-
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Tb-Eu, which were surface functionalized with azides, and alkyne functionalized ICG
clicked on the surface. It is hypothesized that, in a solution with BSA the particulate
composite can undergo FRET and emit a IR photon that can be enhanced by BSA
(Figure 4.4a). Alkyne modified indocyanine green dye has a peak absorption at
780 nm, however it has a tail absorption between 600 - 750 nm which can couple to
SiO2 /YPS:Ce-Tb-Eu second major peak at 690 nm (Figure 4.4b). A one pot synthesis was used with similar conditions as the BSA CuAAC onto the SiO2 /YPS:Ce
particulates, where alkICG was bonded to SiO2 /YPS:Ce-Tb-Eu. FRET is distance
dependent where the donor and acceptor must be within 10 nm from one another.
CuAAC is advantageous for FRET since it covalently bonds two molecules within this
10 nm margin. Photoluminescence in (Figure 4.4c) supports FRET occurring between the SiO2 /YPS:Ce-Tb-Eu and ICG from the 825 nm band when excited at 250
nm. Uv excitation does not generate a photon for ICG however this excitation source
does excite SiO2 /YPS:Ce-Tb-Eu. Therefore, the band at 825 nm can be inferred from
FRET between SiO2 /YPS:Ce-Tb-Eu and ICG. Visual luminescence was obtained by
a IVIS in-vivo imaging system under both IR and X-ray irradiation (Figure 4.5a
and d). While the geometry of this system is suited for IR irradiation as seen by
the entire eppendorf emitting, X-rays can localize its targeting. A diminishing return
on the particulate’s emission was obtained between 1-5 mg/mL when irradiated by
both IR and X-ray photons (Figure 4.5b and e). In both cases the irradiation
can penetrate through porcine tissues and generate enough photons to be detected
by the IVIS (Figure 4.5c and f). While this system has the potential to be used
as a IR biotracer and in therapeutics for photothermal therapy, ICG is notorious for
its instability in aqueous environment and alternative composite systems should be
explored.
A more reliable photosensitizer for theranostics is RB which can generate
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Figure 4.4: (a) Schematic of energy transfer between SiO2 /YPS:Ce-Tb-Eu, ICG, and BSA. (b)
Spectral overlap between absorption of ICG and photoluminescence of SiO2 /YPS:Ce-Tb-Eu. (c)
Photoluminescence of SiO2 /YPS:Ce-Tb-Eu/ICG when irradiated at 250 nm, where ICG’s peak can
be observed at 825 nm.

ROS when it absorbs electromagnetic radiation at 560 nm. Photoluminescence of
SiO2 /YPS:Ce-Tb shows five bands at 390 nm, 493 nm, 542 nm, 590 nm, and 623 nm
corresponding to the electron transition states from cerium’s 5d orbital to the 4 D7/2
state and terbium’s 5 D4 state to the 7 F6 , 7 F5 , 7 F4 , and 7 F3 states respectively[154].
In this particle design, cerium acts as a sensitizer for terbium to enhance its emission. SiO2 /YPS:Ce-Tb photoluminescence is favorable for resonance energy transfer
with the alkyne modified RB which has a absorption peak at 560 nm as suggested
by Figure 4.6a. By inspecting the two traces, terbium’s emission can couple to RB
while cerium’s emission would be unaltered by RB. Two particles were engineered
for this work via CuAAC with SiO2 /YPS:Ce-Tb as the transducer and RB as the
photosensitizer. The first particle synthesized was SiO2 /YPS:Ce-Tb clicked with RB
(SiO2 YPS:Ce-TB/RB) and the second is SiO2 /YPS:Ce-Tb clicked with both RB and
bovine serum albumin (SiO2 YPS:Ce-Tb/RB-BSA). In both designs of SiO2 /YPS:CeTb/RB and SiO2 /YPS:Ce-Tb/RB-BSA, the photoluminescence peak intensity ratio of cerium and terbium decreased by 42% and 35%, respectively (Figure 4.6b).
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Figure 4.5: (a) Photoluminescence image of SiO2 /YPS:Ce-Tb-Eu/ICG dispersed in PBS and BSA
(1:40 w/w particle to BSA) when irradiated at 745 nm for 3 seconds. (b) Average radiant efficiency
of different concentrations of SiO2 /YPS:Ce-Tb-Eu/ICG when irradiated at 745 nm. (c) Photoluminescence image of SiO2 /YPS:Ce-Tb-Eu/ICG dispersed in PBS and BSA solution under porcine
and irradiated at 745 nm. (d) Photoluminescence image of SiO2 /YPS:Ce-Tb-Eu/ICG dispersed in
PBS and BSA (1:40 w/w particle to BSA) when irradiated with X-rays at 25 kV and 158 µA for 1
minute. (e) Photon counts of different concentrations of SiO2 /YPS:Ce-Tb-Eu/ICG when irradiated
with X-rays . (f ) Photoluminescence image of SiO2 /YPS:Ce-Tb-Eu/ICG dispersed in PBS and BSA
solution under porcine tissue and irradiated with X-rays.
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While the percent difference between the two RB particles is minor the ratio’s decrease suggest that energy transfer between the organic moiety and the transducer is
present. When excited by X-rays, SiO2 /YPS:Ce-Tb/RB and SiO2 /YPS:Ce-Tb/RBBSA showed a percent decrease in terbium’s peak of 36% and 62%, respectively
(Figure 4.6c). In both cases energy transfer between the transducer and the photosensitizer can be observed under UV and X-ray excitation by the decrease in terbium’s
emission at 542 nm when RB is present.
HepG2 cells are part of a hepatoblastoma liver cell line obtained through
biopsy and frequently used for in-vitro cell studies and nanoparticle-cell interaction
[207]. Fluorescence microscopy was used to determine the cell-particle interaction
between HepG2 and the SiO2 /YPS:Ce-Tb particles with RB and BSA (Figure 4.7).
The presence of BSA is commonly used to increase the hydrophilicity of RB when presented in a phosphate buffer solution (PBS) environment, additional BSA is used to
increase the affinity between nanoparticles and cells. Under a red florescence protein
filter (excitation at 555 nm), no detectable signals were obtained from HepG2 (Figure
4.7a-c) while the SiO2 /YPS:Ce-Tb/RB nanoparticles emitted a strong signal that
matches the location of its respective transmission images (Figure 4.7d-f). The
two SiO2 /YPS:Ce-Tb/RB nanoparticles with and without BSA were incubated with
HepG2 cells for 24 hours and examined under same florescence microscopy conditions.
Noticeably, the SiO2 /YPS:Ce-Tb/RB nanoparticles accumulated on the peripheral of
the cell and throughout its surroundings (Figure 4.7g-i) while the SiO2 /YPS:CeTb/RB-BSA nanoparticles were sequestered inside the HepG2 cells through endocytosis (Figure 4.7j-l). The SiO2 /YPS:Ce-Tb/RB-BSA interaction with HepG2 cells
is expected since BSA is a major protein constituent of blood plasma and has a major
role in transportation of different ligands in the body, which would cause the particles
to have high affinity with cells[208]. More importantly, in theranostics the engineered
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Figure 4.6: (a) Spectral overlap between the photoluminescence of SiO2 /YPS:Ce-Tb excited at
338 nm and absorption of RB. (b) Photoluminescence of SiO2 /YPS:Ce-Tb, SiO2 /YPS:Ce-Tb/RB,
and YPS:Ce-Tb/RB-BSA excited at 338 nm. Decrease in the photoluminescence ratio of cerium and
terbium bands were observed with the presence of RB. This would suggest energy transfer is present
between SiO2 /YPS:Ce-Tb and RB. (c) Radioluminescence of SiO2 /YPS:Ce-Tb, SiO2 /YPS:CeTb/RB, and SiO2 /YPS:Ce-Tb/RB-BSA excited at 25 kV and 158 µA.
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nanoparticles should be ingested by the targeted cancer cells to increase the probability of cell death [209]. In this example, CuAAC was used to bind azide modified RB to
alkyne modified BSA and then to the azide modified SiO2 /YPS:Ce-Tb nanoparticles.
Spin trapping coupled with electron paramagnetic resonance (EPR) was used
to determine the types of radical produced when X-rays are exposed to SiO2 /YPS:CeTb/RB and SiO2 /YPS:Ce-Tb/RB-BSA. This technique uses a spin-trap that can
scavenge short lived radicals (i.e hydroxide) into more stable nitroxide radials where
the original radical’s EPR spectral can be obtained [210]. 5-5 Dimethyl-1-pyrroline Noxide (DMPO) is a hydrophilic non-discriminatory spin-trap that can form a stable
adduct by Figure 4.8a [211]. The types of radicals obtained through spin trapping can be identified by the hyperfine splitting pattern, which originate from interactions between electron spin with neighboring nuclear spin [212]. In the case of
SiO2 /YPS:Ce-Tb/RB exposed to X-rays, its EPR spectrum has seven hyperfine splitting patterns that matches the simulation of free radicals produced by hydroxides and
degradation products from DMPO (Figure 4.8b-c). When SiO2 /YPS:Ce-Tb/RBBSA was exposed to X-rays both the degradation and hydroxide radical were present
additionally a methyl radical was generated (Figure 4.8d-e). In X-PDT the free
radicals are generated by the aqueous surroundings when the high energy X-rays
break apart water molecule as well as the photosensitizer. In this case of RB, the free
radicals are type II radicals generated by the formation of singlet oxygen (1 O2 ) from
its ground state (3 O2 ) via the energy transfer between the SiO2 /YPS:Ce-Tb and RB.
In the presence of BSA, it can be speculated that the high energy X-rays are degrading the protein and not generated by a secondary reaction between the free radicals
since BSA is known as a scavenger [213]. Both types of particulates exhibit free
radical generation that are toxic toward cancer cells with SiO2 /YPS:Ce-Tb/RB-BSA
nanoparticle having favorable cell interaction and additional radical being generated
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Figure 4.7: Optical images of HepG2 cells (a) without any filters, under (b) a red florescence
protein (RFP) filter, (c) and overlay of the two images. Optical images of SiO2 /YPS:Ce-Tb/RB cells
(d) without any filters, under (e) a RFP filter, (f ) and overlay of the two images. Optical images
of HepG2 cells and SiO2 /YPS:Ce/Tb-RB incubated together for twenty four hours (g) without
any filters, under (h) a red florescence protein filter, (i) and overlay of the two images. Optical
images of HepG2 cells and SiO2 /YPS:Ce/Tb-RB/BSA incubated together for twenty four hours (j)
without any filters, under (k) a red florescence protein filter, (l) and overlay of the two images.
Transmission images were used to guide the eye on cell-particle interaction. No signals of HepG2
cells were obtained under a RFP filter, while the different RB variants emitted a signal that can
be differentiated by HepG2. When the two images were overlaid with one another, SiO2 /YPS:CeTB/RB gather on the surface of the particle, whereas SiO2 /YPS:Ce-Tb/RB-BSA was readily seen
inside the cells.
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by X-rays.
In-vitro experiments with HepG2 cells and SiO2 /YPS:Ce-Tb/RB-BSA were
performed to further investigate the viability of this particulate system for X-PDT.
The HepG2 cells were incubated with the particulates for 24 hours followed by reasonable X-ray exposure (1-2 Gy) generated at 25 kV and lastly cytotoxicity was assessed
after another 24 hours using a MTS assay. Figure 4.9 presents four conditions
explored. First a baseline of the cells without any X-ray exposure and interaction
with SiO2 /YPS:Ce-Tb/RB-BSA was obtained. When incubated with SiO2 /YPS:CeTb/RB-BSA for 24 hours no cell death was observed, indicating that this potential
transducer for X-PDT is non-toxic for an acute time period. As one would expect,
when the HepG2 cells were exposed to X-rays without SiO2 /YPS:Ce-Tb/RB-BSA the
cancer cell had a increase in cell death due to the radicals generated by radiotherapy
with X-rays. In this exposure condition, on average, 68% of the HepG2 cells survived
relative to the HepG2 cells unexposed to both particles and X-rays. When the HepG2
cells were exposed to X-rays along with SiO2 /YPS:Ce-Tb/RB-BSA cell viability on
average decreased to 52% which still is statistically different compared to the cells
only exposed to X-rays by one way analysis of variance with post-hoc Tukey analysis.

4.3

Conclusion
This chapter presented multifunctional SiO2 /YPS nanoscintillators synthe-

sized by the HTMcR with organic moieties using CuAAC. Both azide and alkyne functional group can be modified on SiO2 /YPS, both of which are major constituents for
CuAAC. Three types of organic moieties were clicked onto the scintillating nanoparticles to provide X-ray sensitive properties that traditionally are not found in small
molecules. First bovine serum albumin was covalently bonded onto the YPS sur88

0

-70000

3500

140000
140000
0
70000
70000
70000
-70000
0

00
-140000
-70000
140000
-70000
-70000

-140000
70000
-140000
-140000
140000
0

O

3520

YPS+RB

-70000

-140000

3540

3560

70000

BSA

0

140000
140000
140000
140000

140000

YPS+RB

0
0
0

-140000
-140000
70000
-140000
140000

Sys1+Sys2
BSA
Sys1+Sys2RB

b)

70000
70000
70000

-70000
-70000
140000
-70000

Sys1+Sys2

3480

simulation
YPS+RB
H + HO
3480
3480
3480

3500
3500
3500

3520
3520
3520
field

3540
3540
-140000
3540
140000

d)

70000

0
3480

3500

3520

simulation
H + HO
simulation

3540

3500

3520

3480
3480

3500
3500

3520
field
3520

c)

O

3500

3520

3540

3560

YPS+RB

0
0
00

simulation
H + HO
-OX+ OH

-140000
YPS+RB+BSA
3560
3480
3500
3520 YPS+RB+BSA
3540
3560
3560-140000
-140000
-140000
3480
3500
3520
3540
3560
3480
3500 3480
3520 3500
3540field
3560 3540
3480
3500
3520
3540
3560
3560
3520
3560
140000
140000
140000

70000
70000
70000

e)

0
00

3560

-70000
-70000
-70000

YPS+RB+BSA
3540
3560
-140000
3540
3540

3480

70000
70000
70000

-70000
-70000
-70000

-70000

H +3480
HO

R

N

70000

-70000
-70000

N

RBSys1+Sys2
RB

140000
140000
140000

H

N

Sys1+Sys2
N
N

-140000

H

+R

a)

RB
BSA
BSASys1+Sys2

0

simulation
-OX+
OH +CH3 simulation
H + HO
simulation

-140000
-140000
-140000
3480
3500
3520
3540
3480
3500 3480
3520 3500
3540 3520
3560 3540
3560
3480
3500
3520
3540
3560

K

field

3560
3560
3560

K
field

Figure 4.8: (a) Mechanism of DMPO and its interaction with a radical. (b) EPR spectral of
SiO2 /YPS:Ce-Tb/RB with 5 mmol of DMPO when irradiated by X-rays in a aqueous environment. (c) Simulation of hydroxide radicals (OH) and degradation products (-OX) of DMPO that
matches the EPR spectral of SiO2 /YPS:Ce-Tb/RB when irradiated by X-rays. (d)EPR spectral of
SiO2 /YPS:Ce-Tb/RB-BSA when irradiated by X-rays. (e) Simulation of hydroxide radicals (OH),
methyl radicals (CH3 ), and degradation products (-OX) of DMPO that matches the EPR spectral
of SiO2 /YPS:Ce-Tb/RB-BSA. All simulations were performed in EasySpin.
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Figure 4.9: Cytotoxicity of HepG2 cell interaction with SiO2 /YPS:Ce-Tb/RB-BSA and the particulate’s radioluminescence. All HepG2 cells were incubated with SiO2 /YPS:Ce-Tb/RB-BSA for
twenty four hours followed by another twenty four hours incubation period before MTS assay were
performed. X-ray’s energy was set at 25 kV, 158 µA, for 6 minutes. The X-ray conditions correlate
between 1-2 Gys by RADTrige50 sensors.
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face to reduce toxicity that may be present for potential in-vivo studies. ICG dye
was clicked onto the brightest tri-doped SiO2 /YPS particles with IR and X-ray sensitivity. The deep penetrating X-rays could be absorbed by SiO2 /YPS:Ce-Tb-Eu
and transfers its energy to ICG and emit infrared emissions through porcine tissues.
Lastly, two variations of RB was clicked onto SiO2 /YPS:Ce-Tb (SiO2 /YPS:Ce-Tb/RB
and SiO2 /YPS:Ce-Tb/RB-BSA) where the co-clicked particulate with BSA and RB
showed higher affinity towards HepG2 cells, produced three types of radicals as inspected by EPR, and has potential to increase cancer cell death. When coupled with
organic moieties, the multidoped SiO2 /YPS nanoparticles synthesized by the HTMcR
provides new X-ray responsive functionalities that cannot be obtained by a singular
particle system.

4.4
4.4.1

Experimental
Synthesis of multi-doped SiO2 /YPS nanoparticles
All sets of particulates were synthesized using the same methodology in chapter

2. The dopant and its respective concentrations were selected based on the most
photons produced when exposed to X-rays as presented in chapter 3 and can optically
couple with the organic dyes of interest.

4.4.2

Synthesis of (3-azidopropyl)trimethoxysilane
(3-chloropropyl)trimethoxysilane (10.06 mmol) was added to 6 mL of dry

dimethylformamide (DMF) with sodium azide (15.1 mmol). The reaction was heated
to 90◦ C for one hour and filtered through fiber glass. The stock solution of (3azidopropyl)trimethoxysilane was stored in a dry box for future use.
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4.4.3

Synthesis of alkyne modified bovine serum albumin
(alkBSA)
BSA was modified with azide functional groups by a N-hydroxysuccinimide

reaction. 1mM of BSA was dissolved in 1x PBS while 21 mM 3-azidopropanoate-Nhydroxysuccinimide ester was dissolved in THF. The two solutions were mixed with
a final concentration of 6.25% THF for 24 hours followed by dialyze for 72 hours.

4.4.4

Synthesis of alkyne modified indocyanine green (alkICG)
4-(1,1,2-Trimethyl-1H-BenzoIndolium-3-yl)Butane-1-Sulfonate was first syn-

thesized by dissolving 2,3,3-trimethyl-4,5-benzo-3H-indole (0.6g, 2.87mmol) in 1,4butane sultone (1.17 g, 8.59 mmol) and heated at 120◦ C for 2 hours. The product
was cooled, crystallized with acetone, filtered, and dried. The sulfanated product
(0.3g, 0.88 mmol) and glutaconealdehyde dianil hydrochloride (0.27 g, 0.96 mmol)
was dissolved in acetic anhydride (4mL) and acetic acid (1mL) at 110◦ C for 2 hours.

4.4.5

Synthesis of alkyne modified rose bengal (alkRB)
RB dye (0.98 mmol) was dissolved in DMF (10 mL) with propargyl bromide

(1.97 mmol) at 80◦ C for 3 hours. The solution was evaporated under reduced pressure
and the residuals was dissolved in a mixture of dichloromethane and methanol (1:1
v/v). Ethanol was used to precipitate the dye and separated through centrifugation.
A portion of the alkyne modified RB was dissolved in dimethyl sulfoxide for NMR.
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4.4.6

Synthesis of azide modified rose bengal (azRB)
1-azido-3-iodopropane was synthesized by a previous report [214]. RB dye (0.2

g, 0.197 mmol) was dissolved in DMF (3 mL) along with 1-azido-3-iodopropane (62
mg, 0.295 mmol) at 80◦ C for 3 hours. The solution was then precipitated out and
washed with ethanol. The residuals were dissolved in acetone and precipitate out
using hexane.

4.4.7

(3-azidopropyl)trimethoxysilane surface modification on
SiO2 /YPS (azYPS)
YPS (200 mg) particles were dispersed in a 9:1 v/v of methanol and water (30

mL) with 270 µL of ammonia hyroxide (8.6 mmol) and 100 µL of az-sil The reactants
were reflux at 80◦ C for 1 hour and washed with methanol (3x).

4.4.8

Surface modification of SiO2 /YPS with polypropargyl
acrylate (YPS/PPA)
YPS particulates (400 mg) was dispersed in 60 mL of a mixed solution of DI

water and methanol (1:9 v/v) with 200 µL of MPS and 560 µL of ammonia hydroxide.
The suspension was mixed for 20 hours and refluxed for 20 mins.
The YPS particulates modified with MPS (100 mg) was dispersed in 8 mL
of DI water with propargyl acrylate (50 µL), sodium dodecyl sulfate (6 mg), and
potassium persulfate (7 mg) at 65◦ C for 4 hours. The particulates were washed with
methanol (3x).

93

4.4.9

Click chemistry azYPS particulates with alkBSA
A 1:2 mass ratio of alkBSA to azYPS particles was used while a 1:2 molar

ratio of alkBSA and copper sulfate and a 1:5 molar ratio of alkBSA and sodium
ascorbate was used. YPS particulates (100 mg) was dispersed in 1.67 mL of DI
water, while copper sulfate pentahydrate (0.375 mg) and sodium ascorbate (0.745
mg) were dissolved in 0.416 mL of water. The alkBSA was dissolved in 1.22 mL
1x PBS. The azYPS and alkBSA were reacted in a J-KEM mini-reactor at 28◦ C
followed by the addition of copper sulfate solution and then the sodium ascorbate
solution for 24 hours in a dark environment with a constant purge of nitrogen. The
azYPS/alkBSA particles were washed multiple times, first with 1x PBS and EDTA
followed by DI water and 1x PBS.

4.4.10

Click chemistry of alkyne modified small molecules
with azide modified YPS

All azYPS particulates were modified with each of the respective small molecules
previously mentioned at 1 wt%. alkRB was clicked onto YPS:Ce-Tb and alkICG was
clicked onto YPS:Ce-Tb-Eu. The same molar ratios of copper sulfate and sodium
ascorbate to small molecules was used as the section above. A constant volume ratio of 4:1 for methanol and DI water was used throughout each experiment. All
azYPS particulates were dispersed in methanol followed by the addition of the different types of small molecules. The catalyst and reducing agents were titrated into
J-KEM mini-reactor using the same conditions as above. All functionalized particulates were washed using DI water with EDTA first followed by continuous washing
with water and methanol. UV-vis was used to check all unreacted small molecules
were removed.
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4.4.11

Click chemistry of alkBSA and small molecules with
azYPS

A 1:2 mass ratio of BSA to azYPS was used for the azYPS/alkBSA-azICG and
azYPS/alkBSA-azRB. Each reaction used 100 mg of BSA and 200 mg of azYPS. The
amount of small molecules used were calculated based on number of azide groups on
the small molecules, since BSA has 40 clickable site the amount of organic molecules
clicked onto the site was chosen to be 20. Each of the small molecules were dissolved
in THF (3 mL), while BSA was dissolved in DI water (2 mL) with copper sulfate
pentahydrate (1:2 molar ratio of dye to copper sulfate pentahydrate) and sodium
ascorbate (1:5 molar ratio of dye to sodium ascorbate) for one hour. Afterwards the
particulates were dispersed in 1 mL mixture of THF and DI water (4:6 v/v) and
added to the J-Kem reaction vessel for 24 hours. The final particulates were washed
in a mixture of THF and PBS (4:6 v/v) until no absorbance of the dye was detected
in the decant by UV-vis. The final particulates were dispersed in PBS.

4.4.12

Material characterization

A Hitachi TEM 9500 and Hitachi TEM 7830 was used to obtain TEM images
of the multifunctional nanoparticles. Uv absorption was obtained by a PerkinElmer
Uv/vis/NIR spectrometer Lambda 950. X-ray luminescence was obtained by the
same previous method stated in early chapters. Photoluminescence in the IR range
was obtained by a photon technology international fluorescence/luminescence spectrometer, while photoluminescence in the visible light spectrum was obtained by the
JobinYoven spectrometer, stated in previous chapters. X-ray and photoluminescence
imaging of SiO2 /YPS:Ce-Tb particulates with porcine tissues were obtained by a
IVIS Lumina-XR imaging system. EPR measurements were taken on a Bruker EMX
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EPR, the particles were dispersed into a phosphate buffer solution with 0.5 mmol
of DMPO, irradiated with X-rays by a Bruker benchtop X-ray diffractometer, and
sequestered by a quartz capillary.
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Chapter 5
Conclusions
The objective of the presented work is to develop a nanoparticle platform that
can leverage the fully penetrating X-rays energies with bright inorganic scintillators
as an alternative theranostics tool compared to near infrared systems. This was
accomplished by developing a new technique that would prevent the aggregation of
refractory nanomaterials during the synthetic process. Followed by tailoring and optimizing the emission generated by these sub-100 nm scintillators using different doping
strategies with cerium, terbium, and europium. By copper assisted azide-alkyne cycloaddition click chemistry, organic molecules can be covalently bonded onto the surface of these nanoparticles to added new biological functions. The organic molecules
explored were bovine serum albumin to increase the nanoscintillators biocompatibility, indocyanine green dye as a infrared tracer, and rose bengal as photosensitizer
to generate reactive oxygen species. These sub-100 nm scintillators can find uses for
next generation biomedical diagnosis and therapeutics such as X-ray optogenetics,
X-ray luminescence imaging techniques, and X-ray induced photodynamic therapy.
Synthesis of refractory nanoscintillators by a high temperature multicomposite reactor Rare earth silicate nanoparticles and their derivatives are promis97

ing candidates for X-ray related applications in the biomedical field such as lutetium
oxyorthosilicate, yttrium pyrosilicate, and lutetium pyrosilicate. The problem is the
high temperature requirement to synthesize these crystals. A solution is presented
and coined the high temperature multi-composite reactor. The technique is a multistep process where a core-bishell architecture is formed. Silica nanoparticles were first
synthesized using the Stöber process such that this core becomes the size and chemical
template for the scintillating silicate nanoparticle. A 10.5 nm yttrium hydrocarbonate
shell doped with cerium (0.75 mol% relative to yttrium) was deposited onto the silica
core and oxidized at 750◦ C to obtain a SiO2 /Y2 O3 :Ce core-shell nanoparticle. The surface of the core-shell nanoparticle was functionalized with 3-(trimethoxysilyl)propyl
methacrylate under reflux condition. Free radical polymerization of divinylbenzene
was performed to obtain a SiO2 /Y2 O3 :Ce/pDVB core-bishell architecture. When
annealed at 1100◦ C the core and shell recrystallized to yttrium pyrosilicate while
the pDVB carbonized to amorphous carbon and prevented particle-particle contact.
Lastly, the annealing temperature was reduced to 800◦ C to remove the amorphous
carbon with SiO2 /YPS:Ce as the final particle. X-ray diffraction indicated that the
nanoscintillators crystallized into the P1̄ space group of yttrium pyrosilicate. Applying the Scherrer equation to the diffraction trace suggested crystallite size growth
from 0.75 nm to 8 nm when annealed from 1- 36 hours. Electron microscopy confirmed the non-aggregated state of the SiO2 /YPS:Ce when the high temperature
multi-composite reactor was applied, furthermore the same SiO2 /Y2 O3 :Ce sintered
without the sacrificial delamination layer. Electron dispersive spectroscopy provided
a qualitative analysis of the elemental distribution of SiO2 /YPS:Re structure where
silicon and oxygen were predominately in the core while the yttrium and cerium
species are on the peripheral of the particulates. The highest optical light output
under UV radiation was 24 hrs. A red shift in its X-ray luminescence compared
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to the particulates photoluminescence which was attributed to the X-ray emission
of YPS:Ce and silica. The HTMcR was then applied to lutetium pyrosilicate. The
HTMcR technique prevented aggregation up to 1300◦ C and the diffraction trace suggested a conversion from the P1̄ space group to the C2/m space group. When both
SiO2 /YPS:Ce and SiO2 /LPS:Ce were incubated with human embryonic kidney cells
for a acute time period of 48 hours no toxicity was observed. The results in chapter
2 presents a new technique to synthesize nanosized scintillators at temperatures that
were conventionally thought to sinter nanoparticles.
Enhancement of cerium’s, terbium’s, and europium’s X-ray luminescence through doping strategies The technique developed from chapter 2
opened new nanocrystals that have ideal size requirements for in-vivo experiments.
However, the optical emission of nanoparticles in biomedical research is just as important as its size. In chapter three, the optical properties of cerium, terbium, and
europium embedded in a YPS lattice were studied under UV and X-ray irradiation.
First different concentrations of terbium and europium were mono-doped inside the
SiO2 /YPS particulates. A doping concentration at 10 mol% and 15 mol% of terbium
and europium had the greatest X-ray luminescence when mono-doped, respectively.
The X-ray luminescence of terbium and europium could further be enhanced using
a multi-doping strategy. Terbium’s emission could be enhanced when a cerium sensitizer is introduced. Four sets of SiO2 /YPS:Ce-Tb were synthesized each with a
constant concentration of cerium at 0.75 mol% and varying degree of terbium at 1
mol%, 3 mol%, 5 mol%, and 10 mol%. Each of the co-doped particulates has a greater
optical output compared to the mono-doped terbium particulate at 10 mol% when
irradiated with X-rays. A tri-doped system was used to enhance the optical output of
europium where cerium and europium were doped at a constant concentration at 0.75
mol% and 15 mol%, respectively while a terbium bridge was created with a doping
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concentration at 1 mol%, 10 mol%, and 15 mol%. Similarly, the tri-doped system has
a greater X-ray luminescence when the terbium bridge was at 10 mol% and 15 mol%
compared to the mono-doped europium system at 15 mol%. It was also observed that
all the multi-doped particulates could be excited at 338 nm and 250 nm, where the
spectral pattern was cerium with the f-f transition emission and only the f-f emission,
respectively. Each of the rare earths explored in this chapter have the potential to
couple with different light sensitive proteins such as ChR2, ArchT, and ReaChR. The
work provided in this chapter laid the foundation to optically couple nanomaterials
with biological conjugates or organic moieties.
Biological functionalization of SiO2 /YPS via copper assisted azidealkyne cycloaddition click chemistry Research in nanophosphor for the intended
use in biomedical applications has recently evolved into a singular platform with multiple functionalities that can accommodate the complex nature of the body. The high
temperature multi-composite reactor can synthesize inorganic scintillating nanoparticles however, to achieve multiple functionality and reduce the toxicity of these materials a composite system composed of a inorganic core and a organic shell should
be used. In order to achieve this composite nanosystem, copper azide-alkyne cycloaddition was implemented as a facile and reliable method between the inorganic
scintillator and different organic moieties. (3-azidopropyl)trimethoxysilane was used
to functionalize the surface of the brightest differently doped SiO2 /YPS particulates
with a azide functional group. Three organic moieties were explored in this work in
which all of the organic moieties were functionalized with a alkyne group: 1) bovine
serum albumin, 2) indocyanine green dye, and 3) rose bengal. Electron microscopy
confirmed the attachment of BSA on SiO2 /YPS:Ce. ICG was then bonded onto
SiO2 /YPS:Ce-Tb-Eu where Forester resonance energy transfer was observed by spectroscopy and visually. First the composite nanoparticle with ICG was exited under
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UV (250 nm) irradiation where ICG emission was observed at 845 nm, a excitation
wavelength that normally does not excite ICG but the tri-doped SiO2 /YPS:Ce-TbEu. Visual observation of the particle to indocyanine green dye energy transfer was
observed using a IVIS in-vivo imaging system where the X-rays were localized onto a
solution of SiO2 /YPS:Ce-Tb-Eu/ICG particulates in which the energy of X-rays were
able to penetrate porcine tissues and indocyanine green’s emission could be detected.
Lastly, rose bengal was bonded onto SiO2 /YPS:Ce-Tb where a strong spectral overlap
can be observed at 550 nm. In this system, PL and RL were used to assess the energy
transfer between the particulate and rose bengal where the peak ratio of terbium
decreased with the attachment of RB and its variations. Electron paramagnetic resonance confirmed the generation of reactive oxygen species when YPS:Ce-Tb/RB and
its variations when irradiated by X-rays. Particle-cell interaction was evaluated with
florescence microscopy and in-vitro toxicity studied by a MTS assay. When YPS:CeTb was clicked with rose bengal and bovine serum albumin, the HepG2 cells ingested
the particulates while the uncoated YPS:Ce-Tb particles with rose bengal aggregated
onto the surface of the cells. The former behavior being more favorable to localize
the generation of reactive oxygen species to cancerous cells. Cytotoxicity of HepG2
cells were evaluated using a MTS assay when YPS:Ce-Tb/Rb-BSA was incubated
with HepG2 cells and exposed between 1-2 Gy(s) of X-rays. The toxicity resulted
in a statistically significant increase in cell death by 10% when YPS:Ce-Tb/Rb-BSA
particulates are present with HepG2 cells and X-rays compared to HepG2 cells under radiotherapy. The three nanocomposites presented in this work have possible
applications in medical theranostics where BSA can be used to reduce toxicity and
enhance dye emissions, ICG as an IR biomarker and PTT system, and RB as a ROS
generator for X-PDT where the inorganic scintillator is used as a transducer for its
excellent X-ray stopping power.
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5.1

Recommendations for Future Research
The high temperature multi-composite reactor is a novel technique that should

be used to explore new nanocrystals that have high crystallization temperatures where
it is traditionally impossible to synthesize due to sintering. Chapter 2 discusses the
synthesis of pyrosilicate nanoparticles for their scintillating properties, however other
sub-100 nm crystals should be explored such as garnet, vanadate, and tantalate structures. Each of the thee crystal types have scintillating properties that can efficiently
absorb high energy radiation due to its large atomic number. Furthermore, these
crystals are difficult to synthesize due to its high crystallization temperature, however with the HTMcR these crystals have the potential to be synthesized at the
sub-100 nm that can be implemented for biomedical purposes. While the desired
oxyorhtosilicate phase was not synthesized this can open opportunities for rare earth
silicate materials. Other strategies can be applied to target this phase such as using
a mesoporous silica template that is infused with rare earth oxides which would be
more thermodynamically favorable for oxyorthosilicate formation. By investigating
different nanoparticle structures and applying the HTMcR, the molar ratios of the
two oxides have the potential to be skewed towards the oxyorthosilicate phase. While
impurities in the inert gases may have limited the synthesis of SiO2 /LPS:Ce, doping
the SiO2 /YPS:Ce particulate with Lu3+ has the potential to recrystallize the silicate
nanoparticles at 1100◦ C while increasing the efficiency to absorb X-rays. Chapter
3 discusses the X-ray luminescence and energy transfer of cerium, terbium, and europium for optogenetics and X-ray photodynamic therapy. In the three different
series presented, a local minimum was determined for the tri-doped series. However,
further investigation into different concentrations of europium and terbium can be
investigated to find a global maximum in regards to its X-ray luminescence. The
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concentration for the terbium bridge and europium emitters were selected based on
established work in the literature, but with the HTMcR new structures can be made
that may have unique energy transfer process not observed before. Further work could
expand on other dopants that can be incorporated to the SiO2 /YPS particulate such
as thulium, dysprosium, and holmium. Similarly, the same doping strategies can be
applied to different lanthanide combination and explore other optical phenomenon
such as upconversion or obtain different emission bands that are suited for other biological conjugates. Lastly, chapter 4 presents three different biological conjugates
that can be applied to theranostics which, includes a method to increase nanoparticle
affinity with cells, a infrared tracer, and a photosensitizer that can generate ROS
when excited by X-rays. Other moieties can be coupled to the nanoscintillators and
explore its potential in the biomedical field. In the case for cell affinity, a biological
protein was explored, however this list can be expand to peptides that can bind to
specific cell receptors. Other organic dyes can also be clicked onto the scintillating
nanoparticles synthesized by the high temperature multi-composite reactor such as
squaraine and tetrapyyrole family. These dyes have photophysical properties that
may be desired for different biomedical applications. Long term toxicity of these
nanoparticles, followed by more in-vitro and in-vivo work should also be investigated.
Nanotechnology in the biomedical field is a staple in materials research that
is ever growing in demand. The past decade has focused primarily on near infrared
emitting nanophosphor since it is optically transparent to tissues. However, near
infrared can only penetrate 3-5 mm of the skin. X-rays on the other hand are fully
penetrating and when coupled with nanoscintillators new theranostics techniques can
be achieved. The high temperature multi-composite reactor is a technique that was
developed to expand the possible nanoscintillators by removing the high temperature
requirements to synthesize superior high-density scintillators. Furthermore, when
103

nanoscintillators are grafted with organic moieties multiple functionalities can be
obtained in a singular platform. Therefore, more inorganic-organic nanoparticles
with X-ray induced luminescence should be investigated to take advantage of the fully
penetrating high energy source of X-rays with the high optical output of inorganic
scintillators and the diverse functionalities of organic systems.
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